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reamble
eeping pace with the stream of new data and evolving
idence on which guideline recommendations are based is
ongoing challenge to timely development of clinical
actice guidelines. In an effort to respond promptly to new
idence, the American College of Cardiology Foundation
CCF)/American Heart Association (AHA) Task Force on
ractice Guidelines (Task Force) has created a “focused
date” process to revise the existing guideline recommen-
tions that are affected by the evolving data or opinion. New
idence is reviewed in an ongoing fashion to more efficiently
spond to important science and treatment trends that could
ve a major impact on patient outcomes and quality of care.
vidence is reviewed at least twice a year, and updates are
itiated on an as-needed basis and completed as quickly as
ssible while maintaining the rigorous methodology that the
CCF and AHA have developed during their partnership of
ore than 20 years.
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August 14, 2012:645–81 2012 UA/NSTEMI Focused UpdateThese focused updates are prompted following a thorough
view of late-breaking clinical trials presented at national
d international meetings in addition to other new published
ta deemed to have an impact on patient care (Section 1.1,
ethodology and Evidence Review). Through a broad-based
tting process, the studies included are identified as being
portant to the relevant patient population. The focused
date is not intended to be based on a complete literature
view from the date of the previous guideline publication but
ther to include pivotal new evidence that may affect
anges to current recommendations. Specific criteria/consid-
ations for inclusion of new data include the following:
publication in a peer-reviewed journal;
large, randomized, placebo-controlled trial(s);
nonrandomized data deemed important on the basis of
results affecting current safety and efficacy assumptions,
including observational studies and meta-analyses;
strength/weakness of research methodology and findings;
likelihood of additional studies influencing current findings;
impact on current and/or likelihood of need to develop new
performance measure(s);
request(s) and requirement(s) for review and update from the
practice community, key stakeholders, and other sources free
of industry relationships or other potential bias;
number of previous trials showing consistent results; and
need for consistency with a new guideline or guideline
updates or revisions.
In analyzing the data and developing recommendations and
pporting text, the writing group uses evidence-based meth-
ologies developed by the Task Force (1). The Class of
ecommendation (COR) is an estimate of the size of the
eatment effect considering risks versus benefits in addition
evidence and/or agreement that a given treatment or
ocedure is or is not useful/effective and in some situations
ay cause harm. The Level of Evidence (LOE) is an estimate
the certainty or precision of the treatment effect. The
riting group reviews and ranks evidence supporting each
commendation with the weight of evidence ranked as LOE
, B, or C using specific definitions that are included in Table 1.
tudies are identified as observational, retrospective, prospec-
ve, or randomized where appropriate. For certain conditions
r which inadequate data are available, recommendations are
sed on expert consensus and clinical experience and ranked
LOE C. When recommendations at LOE C are supported
historical clinical data, appropriate references (including
inical reviews) are cited if available. For issues for which
arse data are available, a survey of current practice among
e clinicians on the writing group is the basis for LOE C
commendations, and no references are cited. The schema
r COR and LOE is summarized in Table 1, which also
ovides suggested phrases for writing recommendations
ithin each COR. A new addition to this methodology is
paration of the Class III recommendations to delineate
hether the recommendation is determined to be of “no
nefit” or is associated with “harm” to the patient. In
dition, in view of the increasing number of comparative
fectiveness studies, comparator verbs and suggested phrases
r writing recommendations for the comparative effective- ofss of one treatment/strategy with respect to another for
OR I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
ectrum of cardiovascular diseases, the Task Force has
signated the term guideline-directed medical therapy
DMT) to represent optimal medical therapy as defined by
CCF/AHA guideline (primarily Class I) recommended ther-
ies. This new term, GDMT, will be used herein and
roughout all future guidelines.
Because the ACCF/AHA practice guidelines address pa-
ent populations (and healthcare providers) residing in North
merica, drugs that are not currently available in North
merica are discussed in the text without a specific COR. For
udies performed in large numbers of subjects outside North
merica, each writing group reviews the potential impact of
fferent practice patterns and patient populations on the
eatment effect and relevance to the ACCF/AHA target
pulation to determine whether the findings should inform a
ecific recommendation.
The ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describ-
g a range of generally acceptable approaches to the diag-
sis, management, and prevention of specific diseases or
nditions. The guidelines attempt to define practices that
eet the needs of most patients in most circumstances. The
timate judgment regarding care of a particular patient must
made by the healthcare provider and patient in light of all
e circumstances presented by that patient. As a result,
tuations may arise in which deviations from these guide-
nes may be appropriate. Clinical decision making should
nsider the quality and availability of expertise in the area
here care is provided. When these guidelines are used as the
sis for regulatory or payer decisions, the goal should be
provement in quality of care. The Task Force recognizes
at situations arise for which additional data are needed to
form patient care more effectively; these areas will be
entified within each respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
commendations are effective only if they are followed.
ecause lack of patient understanding and adherence may
versely affect outcomes, physicians and other healthcare
oviders should make every effort to engage the patient’s
tive participation in prescribed medical regimens and life-
yles. In addition, patients should be informed of the risks,
nefits, and alternatives to a particular treatment and be
volved in shared decision making whenever feasible, par-
cularly for COR IIa and IIb, for which the benefit-to-risk
tio may be lower.
The Task Force makes every effort to avoid actual, poten-
al, or perceived conflicts of interest that may arise as a result
industry relationships or personal interests among the
embers of the writing group. All writing group members
d peer reviewers of the guideline are required to disclose all
rrent healthcare-related relationships, including those ex-
ting 12 months before initiation of the writing effort. In
ecember 2009, the ACCF and AHA implemented a new
licy for relationships with industry and other entities (RWI)
at requires the writing group chair plus a minimum of 50%
the writing group to have no relevant RWI (Appendix 1 for
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e reviewed by the Task Force and all members during each
nference call and/or meeting of the writing group and are
dated as changes occur. All guideline recommendations
quire a confidential vote by the writing group and must be
proved by a consensus of the voting members. Members
e not permitted to draft or vote on any text or recommen-
tions pertaining to their RWI. Members who recused
emselves from voting are indicated in the list of writing
oup members, and specific section recusals are noted in
ppendix 1. Authors’ and peer reviewers’ RWI pertinent to
is guideline are disclosed in Appendixes 1 and 2, respec-
ble 1. Applying Classification of Recommendations and Level
A recommendation with Level of Evidence B or C does not imply that the reco
not lend themselves to clinical trials. Although randomized trials are unavaila
eful or effective.
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use.
†For comparative effectiveness recommendations (Class I and IIa; Level of Evi
rect comparisons of the treatments or strategies being evaluated.vely. Additionally, to ensure complete transparency, writing reoup members’ comprehensive disclosure information—
cluding RWI not pertinent to this document—is available as
online supplement. Comprehensive disclosure information
r the Task Force is also available online at http://www.
rdiosource.org/ACC/About-ACC/Leadership/Guidelines-and-
ocuments-Task-Forces.aspx. The work of the writing group
supported exclusively by the ACCF and AHA without
mmercial support. Writing group members volunteered
eir time for this activity.
In an effort to maintain relevance at the point of care for
acticing physicians, the Task Force continues to oversee an
going process improvement initiative. As a result, in
ence
ation is weak. Many important clinical questions addressed in the guidelines
re may be a very clear clinical consensus that a particular test or therapy is
rent subpopulations, such as sex, age, history of diabetes, history of prior
and B only), studies that support the use of comparator verbs should involveof Evid
mmend
ble, the
in diffe
dence Asponse to pilot projects, several changes to these guidelines
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August 14, 2012:645–81 2012 UA/NSTEMI Focused Updateill be apparent, including limited narrative text, a focus on
mmary and evidence tables (with references linked to
stracts in PubMed), and more liberal use of summary
commendation tables (with references that support LOE) to
rve as a quick reference.
In April 2011, the Institute of Medicine released 2 reports:
linical Practice Guidelines We Can Trust and Finding What
orks in Health Care: Standards for Systematic Reviews
,3). It is noteworthy that the ACCF/AHA practice guide-
nes were cited as being compliant with many of the
andards that were proposed. A thorough review of these
ports and our current methodology is under way, with
rther enhancements anticipated.
The recommendations in this focused update are consid-
ed current until they are superseded in another focused
date or the full-text guideline is revised. Guidelines are
ficial policy of both the ACCF and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
he standing guideline writing committee along with the
rent Task Force identified trials and other key data through
ctober 2011 that may impact guideline recommendations.
n the basis of the criteria/considerations noted in the
reamble and the approval of new oral antiplatelets, a focused
date was initiated to provide guidance on how to incorpo-
te these agents into daily practice. Now that multiple agents
e available, a comparison of their use in various settings
ithin clinical practice is provided. This iteration replaces the
ctions in the 2007 ACC/AHA Guidelines for the Manage-
ent of Patients With Unstable Angina/Non–ST-Elevation
yocardial Infarction (4) that were updated by the 2011
CCF/AHA Focused Update of the Guidelines for the
anagement of Patients With Unstable Angina/Non–ST-
levation Myocardial Infarction (5,6).
To provide clinicians with a comprehensive set of data,
henever deemed appropriate or when published, the abso-
te risk difference and number needed to treat or harm are
ovided in the guideline, along with confidence intervals
I) and data related to the relative treatment effects such as
ds ratio (OR), relative risk (RR), hazard ratio (HR), and
cidence rate ratio.
Consult the full-text version of the 2007 ACC/AHA
uidelines for the Management of Patients With Unstable
ngina/Non–ST-Elevation Myocardial Infarction (4) for pol-
y on clinical areas not covered by the current document.
dividual recommendations updated in this focused update
ill be incorporated into future revisions and/or updates of
e full-text guidelines.
.2. Organization of the Writing Group
or this focused update, members of the 2011 Unstable
ngina/Non–ST-Elevation Myocardial Infarction (UA/NSTEMI)
cused update writing group were invited and all agreed to
rticipate (referred to as the 2012 focused update writing Aoup). Members were required to disclose all RWI relevant
the data under consideration. The writing group included
presentatives from the ACCF, AHA, American Academy of
amily Physicians, American College of Emergency Physi-
ans, American College of Physicians, Society for Cardio-
scular Angiography and Interventions, and Society of
horacic Surgeons.
.3. Document Review and Approval
his document was reviewed by 2 official reviewers each
minated by the ACCF and the AHA, as well as 1 or 2
viewers each from the American College of Emergency
hysicians, Society for Cardiovascular Angiography and
terventions, and Society of Thoracic Surgeons, and 29
dividual content reviewers, including members of the
CCF Interventional Scientific Council. The information on
viewers’ RWI was distributed to the writing group and is
blished in this document (Appendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF and the AHA and endorsed by the
merican College of Emergency Physicians, Society for
ardiovascular Angiography and Interventions, and Society
Thoracic Surgeons.
. Early Hospital Care
.2. Antiplatelet/Anticoagulant Therapy in
atients for Whom Diagnosis of UA/NSTEMI
Likely or Definite: Recommendations
.2.1. Antiplatelet Therapy: Recommendations
ee Table 2, Appendixes 3, 4, 5, 6, and the Online Data
upplement.)
.2.3. Additional Management of Antiplatelet and
nticoagulant Therapy: Recommendations
ee Table 3, Appendixes 3, 4, 5, 6, and the Online Data
upplement.)
.2.3.1. ANTIPLATELET/ANTICOAGULANT THERAPY IN
TIENTS FOR WHOM DIAGNOSIS OF UA/NSTEMI IS LIKELY
R DEFINITE
.2.3.1.1. P2Y12 Receptor Inhibitors. P2Y12 receptor in-
bitor therapy is an important component of antiplatelet
erapy in patients with UA/NSTEMI and has been tested in
veral large trial populations with UA/NSTEMI. The last
rsion of the guideline recommended the use of clopidogrel
patients with UA/NSTEMI because it was the only US
ood and Drug Administration (FDA)–approved P2Y12 re-
ptor inhibitor in this patient population at that time (6).
ince the publication of the last guideline (6), the FDA has
proved 2 additional P2Y12 receptor inhibitors for use in
tients with UA/NSTEMI. The FDA approved the use of
asugrel and ticagrelor based on data from head-to-head
mparison trials with clopidogrel, in which prasugrel and
agrelor were respectively superior to clopidogrel in reducing
inical events but at the expense of an increased risk of bleeding.
The pivotal trial for prasugrel, TRITON–TIMI 38 (Trial tossess Improvement in Therapeutic Outcomes by Optimizing
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2012 UA/NSTEMI Focused Update August 14, 2012:645–81latelet Inhibition with Prasugrel–Thrombolysis in Myocar-
al Infarction) (7), focused on patients with acute coronary
ndrome (ACS) who were referred for percutaneous coro-
ry intervention (PCI). TRITON–TIMI 38 randomly as-
gned 13,608 patients with moderate- to high-risk ACS, of
hom 10,074 (74%) had UA/NSTEMI, to receive prasugrel
60-mg loading dose and a 10-mg daily maintenance dose)
clopidogrel (a 300-mg loading dose and a 75-mg daily
aintenance dose) for a median follow-up of 14.5 months.
cetylsalicylic acid (aspirin) was prescribed within 24 hours
PCI. Clinical endpoints were assessed at 30 and 90 days
d then at 3-month intervals for 6 to 15 months. Among
tients with UA/NSTEMI undergoing PCI, a prasugrel
ading dose was administered before, during, or within 1
ur after PCI but only after coronary anatomy had been
fined. Patients taking any thienopyridine within 5 days of
ndomization were excluded.
Prasugrel was associated with a significant 2.2% absolute
duction and a 19% relative reduction in the primary efficacy
dpoint, a composite of the rate of death due to cardiovas-
lar causes (including arrhythmia, congestive heart failure,
ock, and sudden or unwitnessed death), nonfatal myocar-
al infarction (MI), or nonfatal stroke during the follow-up
riod (see Online Data Supplement). The primary efficacy
dpoint occurred in 9.9% of patients receiving prasugrel and
.1% of patients receiving clopidogrel (HR for prasugrel
rsus clopidogrel: 0.81; 95% CI: 0.73 to 0.90; p0.001) (7).
rasugrel decreased cardiovascular death, MI, and stroke by
8 events (number needed to treat46). The difference in
e primary endpoint was largely related to the difference in
tes of nonfatal MI (7.3% for prasugrel versus 9.5% for
opidogrel; HR: 0.76; 95% CI: 0.67 to 0.85; p0.001). Rates
cardiovascular death (2.1% versus 2.4%; p0.31) and
nfatal stroke (1.0% versus 1.0%; p0.93) were not reduced
prasugrel relative to clopidogrel. Rates of stent thrombosis
ere significantly reduced from 2.4% to 1.1% (p0.001) by
asugrel.
Prasugrel was associated with a significant increase in the
te of bleeding, notably TIMI (Thrombolysis In Myocardial
farction) major hemorrhage, which was observed in 2.4%
patients taking prasugrel and in 1.8% of patients taking
opidogrel (HR for prasugrel versus clopidogrel: 1.32; 95%
I: 1.03 to 1.68; p0.03). Prasugrel was associated with a
gnificant increase in fatal bleeding compared with clopi-
grel (0.4% versus 0.1%; p0.002). From the standpoint of
fety, prasugrel was associated with an increase of 35 TIMI
ajor and non–coronary artery graft bypass (CABG) bleeds
umber needed to harm167) (7). Also, greater rates of
fe-threatening bleeding were evident in the prasugrel group
an in the clopidogrel group: 1.4% versus 0.9%, respectively
R for prasugrel: 1.52; 95% CI: 1.08 to 2.13; p0.01). In
e few patients who underwent CABG, TIMI major bleeding
rough 15 months was also greater with prasugrel than with
opidogrel (13.4% versus 3.2%, respectively; HR for prasu-
el: 4.73; 95% CI: 1.90 to 11.82; p0.001) (7). The net
inical benefit in the TRITON–TIMI 38 study demonstrated
primary efficacy and safety endpoint rate of 13.9% in the
opidogrel group versus 12.2% in the prasugrel group (HR:
87; 95% CI: 0.79 to 0.95; p0.004). reA post hoc analysis suggested there were 3 subgroups of
CS patients who did not have a favorable net clinical benefit
efined as the rate of death due to any cause, nonfatal MI,
nfatal stroke, or non–CABG-related nonfatal TIMI major
eeding) from the use of prasugrel or who had net harm:
atients with a history of stroke or transient ischemic attack
fore enrollment had net harm from prasugrel (HR: 1.54;
% CI: 1.02 to 2.32; p0.04); patients age 75 years had
net benefit from prasugrel (HR: 0.99; 95% CI: 0.81 to
21; p0.92); and patients with a body weight of 60 kg
d no net benefit from prasugrel (HR: 1.03; 95% CI: 0.69 to
53; p0.89). In both treatment groups, patients with at least
of these risk factors had higher rates of bleeding than those
ithout them (7).
The FDA approved prasugrel on July 10, 2009, and cited a
ntraindication against its use in patients with a history of
ansient ischemic attack or stroke or with active pathological
eeding (8). The FDA labeling information includes a
neral warning against the use of prasugrel in patients age
75 years because of concerns of an increased risk of fatal
d intracranial bleeding and uncertain benefit except in
gh-risk situations (patients with diabetes or a history of
ior MI), in which case the net benefit appears to be greater
d its use may be considered (8). In focusing specifically on
tients with UA/NSTEMI, the rate of the primary efficacy
dpoint was significantly reduced in favor of prasugrel
.9% versus 12.1%; adjusted HR: 0.82; 95% CI: 0.73 to
93; p0.002) (7).
The pivotal trial for ticagrelor, PLATO (Study of Platelet
hibition and Patient Outcomes) (9), was a multicenter,
ternational, randomized controlled trial comparing ticagre-
r with clopidogrel (on a background of aspirin therapy) to
termine whether ticagrelor is superior to clopidogrel for the
evention of vascular events and death in a broad population
patients with ACS (see Online Data Supplement). A total
18,624 patients hospitalized with an ACS were randomized
862 centers (from 2006 through 2008). Of those, 11,598
tients had UA/NSTEMI (patients with UA and NSTEMI
ade up 16.7% and 42.7% of the overall population, respec-
vely), whereas 7,026 patients had STEMI.
The primary efficacy endpoint was the time to first occur-
nce of the composite of vascular death, MI, or stroke. The
imary safety endpoint was the first occurrence of any major
eeding event. The randomized treatment was scheduled to
ntinue for 12 months; however, patients were allowed to
ave the trial at 6 to 9 months if the event-driven study
hieved its targeted number of primary events. Overall, the
edian duration of study drug administration was 277 days.
sing a double-blind, double-dummy design, ticagrelor
80-mg loading dose followed by 90 mg twice daily) was
mpared with clopidogrel (300- to 600-mg loading dose
llowed by 75 mg daily) (9). At 24 hours after randomiza-
on, 79% of patients treated with clopidogrel received at least
0 mg, and nearly 20% received at least 600 mg. Overall,
.3% of patients underwent PCI during the index hospi-
lization and 60.6% had stent implantation. Median times
om the start of hospitalization to initiation of study treat-
ent were 4.9 and 5.3 hours for ticagrelor and clopidogrel,
spectively.
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August 14, 2012:645–81 2012 UA/NSTEMI Focused UpdateAt 12 months, ticagrelor was associated with a 1.9%
solute reduction and 16% relative reduction in the primary
mposite outcome compared with clopidogrel (9.8% versus
.7%; HR: 0.84; 95% CI: 0.77 to 0.92), which was driven by
wer rates of MI (5.8% versus 6.9%; HR: 0.84; 95% CI: 0.75
0.95) and vascular death (4.0% versus 5.1%; HR: 0.79;
% CI: 0.69 to 0.91) (9). The benefits of ticagrelor appeared
nsistent across most subgroups studied, with no significant
teraction being observed between the treatment effect and
pe of ACS. In focusing specifically on patients with
A/NSTEMI, ticagrelor was associated with a significant
duction in the primary efficacy endpoint among NSTEMI
tients (n7,955 patients; 11.4% versus 13.9%; HR: 0.83;
% CI: 0.73 to 0.94) but not among UA patients (n3,112
tients; 8.6% versus 9.1%; HR: 0.96; 95% CI: 0.75 to 1.22),
though caution is urged against overinterpreting subgroup
alyses. The benefits of ticagrelor in PLATO appeared within
e first 30 days, persisted for up to 360 days, and were evident
respective of clopidogrel pretreatment and whether patients
d invasive or medical management planned. Notably, ticagre-
r was associated with a 1.4% absolute reduction in all-cause
ortality (4.5% versus 5.9%; HR: 0.78; 95% CI: 0.69 to 0.89)
d with lower rates of definite stent thrombosis (1.3% versus
90%; HR: 0.67; 95% CI: 0.50 to 0.91).
There were no significant differences between the ticagre-
r and clopidogrel groups in rates of major bleeding (the
imary safety endpoint: composite of major life-threatening
d other major bleeding events, PLATO study criteria;
.6% versus 11.2%; HR: 1.04; 95% CI: 0.95 to 1.13), TIMI
ajor bleeding (7.9% versus 7.7%; HR: 1.03; 95% CI: 0.93
1.15), or fatal bleeding (0.3% versus 0.3%; HR: 0.87; 95%
I: 0.48 to 1.59) (9). There were also no differences in major
eeding in patients undergoing CABG, in whom clopidogrel
d ticagrelor were discontinued before the procedure for 5
ys and 24 to 72 hours, respectively, per study protocol.
icagrelor, however, was associated with a higher rate of
n–CABG-related major bleeding (4.5% versus 3.8%,
0.03). In addition, ticagrelor caused a higher incidence of
spnea (13.8% versus 7.8%; HR: 1.84; 95% CI: 1.68 to
02; although not necessitating drug discontinuation except
a few cases), mild increases in creatinine and uric acid
vels, and a higher rate of ventricular pauses 3 seconds in
e first week (5.8% versus 3.6%, p0.01; but without
using differences in syncope or pacemaker implantation).
verall, discontinuation of the study drug due to adverse
ents occurred more frequently with ticagrelor than with
opidogrel (7.4% versus 6.0%; p0.001). Patients with a
story of bleeding were excluded in PLATO, and 4% of
tients had a prior history of nonhemorrhagic stroke (9). The
ficacy and safety of ticagrelor in patients with prior transient
chemic attack or stroke were not reported in PLATO (9),
d the balance of risks and benefits of ticagrelor in this
tient population remains unclear.
A separate analysis was performed for the 5,216 patients in
LATO admitted with ACS and prespecified as planned for
ninvasive management (constituting 28% of the overall
LATO study population) (10). Compared with clopidogrel,
cagrelor was associated with a lower incidence of the
imary endpoint (12.0% versus 14.3%; HR: 0.85; 95% CI: U73 to 1.00; p0.04) and overall mortality without increas-
g major bleeding. These results indicate the benefits of
tensified P2Y12 inhibition with ticagrelor applied broadly
r patients regardless of the intended or actualized manage-
ent strategy (10).
The benefits of ticagrelor in PLATO appeared to be
tenuated in patients weighing less than the median weight
r their sex and those not taking lipid-lowering therapies at
ndomization (9). There was a significant interaction be-
een treatment and geographic region, with patients enrolled
North America having no statistically significant differ-
ces between ticagrelor and clopidogrel with respect to the
imary efficacy endpoint (9). Extensive additional analyses
ere conducted to explore potential explanations for this
teraction between treatment effect in PLATO and geo-
aphic region and whether this could be explained by
ecific patient characteristics or concomitant therapies (11).
ahaffey and colleagues (11) noted that a significantly higher
oportion of patients in the United States received a median
pirin dose of 300 mg daily compared with the rest of the
orld (53.6% versus 1.7%). Indeed, of all 37 baseline and
strandomization variables explored, only aspirin mainte-
nce dose appeared to explain a substantial fraction of the
gional interaction. Of note, subgroup analysis consistently
owed the same aspirin-dose effect outside the United States.
ithout being able to fully rule out the play of chance or
her factors related to clinical care in North America as
planations for the regional interaction, PLATO con-
uded that a low aspirin maintenance dose (100 mg
ily) is likely to be associated with the most favorable
tcomes when using the potent P2Y12 inhibitor ticagrelor
patients with ACS (11).
Because of its reversible inhibition of the P2Y12 receptor,
cagrelor is associated with more rapid functional recovery
circulating platelets and, consequently, a faster offset of
fect than clopidogrel. Although this may represent a poten-
al advantage for patients with ACS undergoing early
ABG, it may theoretically pose a problem for noncompliant
tients (especially given its twice-daily dosing regimen).
The FDA approved ticagrelor on July 20, 2011 (12). The
DA also issued a “Boxed Warning” indicating that aspirin
ily maintenance doses of 100 mg decrease the effective-
ss of ticagrelor, cautioned against its use in patients with
tive bleeding or a history of intracranial hemorrhage, and
vocated a Risk Evaluation and Mitigation Strategy, a plan
help ensure that the benefits of ticagrelor outweigh its risks.
s part of that plan, the manufacturer is mandated to conduct
ucational outreach programs to alert physicians about the
sk of using higher doses of aspirin.
Dual antiplatelet therapy with aspirin and either clopi-
grel or prasugrel has increased the risk of intracranial
morrhage in several clinical trials and patient populations
specially in those with prior stroke) (7,13a,13b,13c). In
LATO, the number of patients with prior stroke was small,
miting the power to detect treatment differences in intracra-
al bleeding in this subgroup (13d). Patients with prior stroke
TIA have been excluded from PEGASUS (Prevention of
ardiovascular Events in Patients With Prior Heart Attack
sing Ticagrelor Compared to Placebo on a Background of
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2012 UA/NSTEMI Focused Update August 14, 2012:645–81spirin), (13e) an ongoing trial of ticagrelor versus placebo in
dition to aspirin in patients with stable coronary artery
sease. Until further data become available, it seems prudent
weigh the possible increased risk of intracranial bleeding
hen considering the addition of ticagrelor to aspirin in
tients with prior stroke or TIA (13f).
.2.3.1.2. Choice of P2Y12 Receptor Inhibitors for PCI
UA/NSTEMI. The writing group cautions that data on
e use of prasugrel and ticagrelor come solely from the
RITON–TIMI 38 and PLATO trials, respectively, and their
e in clinical practice should carefully follow how they were
sted in these studies (7,9). Prasugrel was administered only
ter a decision to proceed to PCI was made, whereas
cagrelor was studied in “all-comer” patients with UA/
STEMI, including invasively and medically managed pa-
ents. The writing group does not recommend that prasugrel
administered routinely to patients with UA/NSTEMI
fore angiography, such as in an emergency department, or
ed in patients with UA/NSTEMI who have not undergone
CI. The FDA package label suggests that it is reasonable to
nsider selective use of prasugrel before catheterization in
bgroups of patients for whom a decision to proceed to
giography and PCI has already been established for any
ason (8). The writing group acknowledges this flexibility,
t it is not its intention to make more specific recommen-
tions about which subgroups of patients might benefit from
asugrel or ticagrelor instead of clopidogrel. The writing
oup does wish to caution clinicians about the potential
creased bleeding risks associated with prasugrel and ti-
grelor compared with clopidogrel in specific settings and
pecially among the subgroups identified in the package
sert and clinical trials (7–9,12). This guideline explicitly
es not endorse one of the P2Y12 receptor inhibitors over the
her. There were several reasons for this decision. Although
e composite efficacy endpoint in TRITON–TIMI 38 favored
asugrel, driven predominantly by a difference in nonfatal
Is (mostly asymptomatic), with deaths and nonfatal strokes
ing similar, bleeding was increased in the prasugrel group
). On the other hand, the composite efficacy endpoint in
LATO favoring ticagrelor over clopidogrel was driven by
fferences in both vascular death and nonfatal MIs, with
roke rates being similar. Ticagrelor was also associated with
notable reduction in all-cause mortality in PLATO.
ompared with clopidogrel, ticagrelor was associated with
higher rate of non–CABG-related major bleeding and
ightly more frequent discontinuation of the study drug
e to adverse events (9). On the other hand, prasugrel was
sociated with a significant increase in the rate of TIMI
ajor hemorrhage, TIMI major and non-CABG bleeding,
well as higher fatal and life-threatening bleeding. There
as a significant interaction between the treatment effect in
LATO and the geographic region, with lack of benefit in
e United States for ticagrelor versus clopidogrel (with
e explanation depending on a post hoc analysis of aspirin
aintenance dose, as noted in the preceding text) (11) (see
nline Data Supplement).
It must be recognized, however, that the 2 newer P2Y12
ceptor inhibitors were studied in different patient popula-
ons and that there is no head-to-head comparative trial of diese agents. Also, the loading dose of clopidogrel in TRI-
ON–TIMI 38 was lower than is currently recommended in
is guideline (7). Furthermore, some emerging studies sug-
st there may be some patients who are resistant to clopi-
grel, but there is little information about the use of
rategies to select patients who might do better with newer
2Y12 receptor inhibitors. Considerations of efficacy in the
evention of thrombosis and risk of an adverse effect related
bleeding and experience with a given medication may best
ide decisions about the choice of P2Y12 receptor inhibitor
r individual patients (14) (Appendix 4).
.2.3.1.2.1. Timing of Discontinuation of P2Y12 Receptor
hibitor Therapy for Surgical Procedures. The writing
oup weighed the current data on the use of P2Y12
ceptor inhibitor therapy in patients who remain hospi-
lized after UA/NSTEMI and are candidates for CABG
d retained the 2007 recommendation (4) of empirical
iscontinuation of clopidogrel therapy for at least 5 days
3) and advocated a period of at least 7 days in patients
ceiving prasugrel and a period of at least 5 days in
atients receiving ticagrelor for their respective discontin-
ation before planned CABG (8,12). Ultimately, the
atient’s clinical status will determine the risk-to-benefit
tio of CABG compared with awaiting restoration of
latelet function.
It is the opinion of the writing group that physicians
d patients should be cautioned against early discontin-
ation of P2Y12 receptor inhibitors for elective noncardiac
rocedures. Given the increased hazard of recurrent car-
iovascular events from premature discontinuation of
2Y12 inhibitors and the increased bleeding risk in pa-
ents undergoing procedures on therapy (e.g., colonos-
py with biopsy, dental procedures), it is advisable to
nsult a cardiologist and preferably defer elective noncar-
iac procedures until the patient finishes the appropriate
urse of P2Y12 receptor inhibition therapy, especially in
A/NSTEMI patients who received 12 months of
eatment with dual antiplatelet therapy after deployment
a drug-eluting stent (DES) (15).
.2.3.1.3. Interindividual Variability in Responsiveness
Clopidogrel. Although clopidogrel in combination
ith aspirin has been shown to reduce recurrent coronary
ents in the posthospitalized ACS population (13,16), the
sponse to clopidogrel varies among patients, and dimin-
hed responsiveness to clopidogrel has been observed
7,18). Clopidogrel is a prodrug and requires conversion
R130964, its active metabolite, through a 2-step process
the liver that involves several CYP450 isoenzymes (19);
these, the CYP2C19 isoenzyme is responsible for almost
lf of the first step formation (20). At least 3 major
netic polymorphisms of the CYP2C19 isoenzyme are
sociated with loss of function: CYP2C19*1, *2, and *3
0 –22). The CYP2C19*2 and *3 variants account for 85%
d 99% of the loss-of-function alleles in Caucasians and
sians, respectively (20). There are racial and ethnic
fferences in the prevalence of these loss-of-function
al
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August 14, 2012:645–81 2012 UA/NSTEMI Focused Updateleles among Caucasians, African Americans, Asians, and
atinos, but all of these groups have some expression
them.
Data from a number of observational studies have demon-
rated an association between an increased risk of adverse
rdiovascular events and the presence of 1 of the nonfunc-
oning alleles (17,18,20,21,23–27) and are well delineated in
e ACCF/AHA Clopidogrel Clinical Alert (20).
Prasugrel, the second FDA-approved P2Y12 receptor in-
bitor for use in ACS, is also a prodrug that requires
nversion to its active metabolite. Prasugrel requires a single
YP-dependent step for its oxidation to the active metabolite,
d at least 2 observational studies have demonstrated no
gnificant decrease in plasma concentrations or platelet
hibition activity in carriers of at least 1 loss-of-function
lele of the CYP2C19 isoenzyme (28,29). On the other hand,
cagrelor, the latest FDA-approved P2Y12 receptor inhibitor,
a nonthienopyridine, reversible, direct-acting oral antago-
st of the P2Y12 receptor that does not require transformation
an active metabolite (30).
Since the FDA announced a “Boxed Warning” on March
, 2010, about the diminished effectiveness of clopidogrel in
tients with an impaired ability to convert the drug into its
tive form (14), there has been much interest in whether
inicians should perform routine testing in patients being
eated with clopidogrel. The routine testing could be for
netic variants of the CYP2C19 allele and/or for overall
fectiveness for inhibition of platelet activity. The ACCF/
HA Clopidogrel Clinical Alert expertly summarizes the
sues surrounding clopidogrel and the use of genotype
sting, as well as the potential for routine platelet function
sting (20).
The FDA label revision does not mandate testing for
YP2C19 genotypes or overall platelet function (14). The
vision serves to warn clinicians that certain patient sub-
oups may exhibit reduced clopidogrel-mediated platelet
hibition and emphasizes that clinicians should be aware of
ternative treatment strategies to tailor alternative therapies
hen appropriate.
A number of commercially available genetic test kits will
entify the presence of 1 of the loss-of-function CYP2C19
leles, but these tests are expensive and not routinely covered
most insurance policies. Additionally, there are no pro-
ective studies that demonstrate that the routine use of these
sts coupled with modification of antiplatelet therapy im-
oves clinical outcomes or reduces subsequent clinical
ents. A recent meta-analysis demonstrated an association
tween the CYP2C19 genotype and clopidogrel responsive-
ss but no significant association of genotype with cardio-
scular events (31). Several ongoing studies are examining
hether genotype assessment with attendant alteration in
tiplatelet therapy for those with loss-of-function alleles can
prove clinical outcomes. On the basis of the current
idence, it is difficult to strongly recommend genotype
sting routinely in patients with ACS, but it might be
nsidered on a case-by-case basis, especially in patients who
perience recurrent ACS events despite ongoing therapy
ith clopidogrel. (3Some argue that clinicians should consider routine testing
platelet function, especially in patients undergoing high-
sk PCI (20), to maximize efficacy while maintaining safety.
gain, no completed prospective studies have examined such
approach to guide such a sweeping change in clinical
anagement. At least 4 randomized clinical evaluation stud-
s being conducted now are testing the hypothesis that
utine platelet function testing should be used to tailor
tiplatelet therapy, and any strong recommendation regard-
g more widespread use of such testing must await the
sults of these trials. The lack of evidence does not mean
ck of efficacy or potential benefit, but the prudent physician
ould maintain an open yet critical mind-set about the
ncept until data are available from 1 of the ongoing
ndomized clinical trials examining this strategy.
Our recommendations for the use of genotype testing and
atelet function testing seek to strike a balance between not
posing an undue burden on clinicians, insurers, and society
implement these strategies in patients with UA or NSTEMI
d that of acknowledging the importance of these issues to
tients with UA/NSTEMI. Our recommendations that the
e of either strategy may have some benefit should be taken
the context of the remarks in this update, as well as the
ore comprehensive analysis in the ACCF/AHA Clopidogrel
linical Alert (20). The Class IIb recommendation of these
rategies suggests that a selective, limited approach to platelet
notype assessment and platelet function testing is the more
udent course until better clinical evidence exists for us to
ovide a more scientifically derived recommendation.
.2.3.1.4. Optimal Loading and Maintenance Dosages
f Clopidogrel. Some have suggested that the loading and
aintenance doses of clopidogrel should be altered to ac-
unt for potential reduced responsiveness to clopidogrel
erapy or that some subgroups of high-risk patients should
treated preferentially with prasugrel (20). Accordingly, the
timal loading and short-term maintenance dosing for clopi-
grel in patients with UA/NSTEMI undergoing PCI is
certain.
Loading and short-term maintenance doses of clopidogrel
ere studied in CURRENT–OASIS 7 (Clopidogrel optimal
ading dose Usage to Reduce Recurrent Events–
rganization to Assess Strategies in Ischemic Syndromes),
ith published data demonstrating a potential benefit of
gher-dose clopidogrel in patients with definite UA/
STEMI undergoing an invasive management strategy
2,33). The CURRENT–OASIS 7 trial randomized 25,086
tients with ACS who were intended for PCI and who were
t considered to be at high risk for bleeding to receive
gher-dose clopidogrel (600 mg loading, 150 mg daily for 6
ys, 75 mg daily thereafter) versus standard-dose clopi-
grel (300 mg loading, 75 mg daily) as part of a 22 design
at also compared maintenance higher-dose aspirin (300 to
5 mg daily) with low-dose aspirin (75 to 100 mg daily). All
tients received 300 mg of aspirin on Day 1 regardless of
ndomization after Day 1. The primary endpoint of the trial
as the combination of cardiovascular death, myocardial
e)infarction, or stroke at 30 days. Although the overall trial
3) failed to demonstrate a significant difference in the
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.2% versus 4.4%), the PCI subset (n17,263) did show
gnificant differences in the clopidogrel arm (32). The
imary outcome was reduced in the PCI subgroup random-
ed to higher-dose clopidogrel (3.9% versus 4.5%;
0.035), and this was largely driven by a reduction in
yocardial (re)infarction (2.0% versus 2.6%; p0.017). Def-
ite stent thrombosis was reduced in the higher-dose clopi-
grel group (0.7% versus 1.3%; p0.0001), with consistent
sults across DES versus non-DES subtypes. Higher-dose
opidogrel therapy increased major bleeding in the entire
oup (2.5% versus 2.0%; p0.012) and the PCI subgroup
.1% versus 0.7%; p0.008). The benefit of higher-dose
opidogrel loading was offset by an increase in major
eeding (32). The findings from the prespecified PCI
bgroup analysis (32) should be interpreted with caution
d considered hypothesis generating, because the primary
dpoint of the CURRENT–OASIS 7 trial was not met and
ven that the p value for interaction (p0.026) between
eatment effect and PCI was of borderline statistical
gnificance.
As noted in the dosing table (Appendix 3), the current
commended loading dose for clopidogrel is uncertain. In
dition, several hours are required to metabolize clopidogrel
its active metabolite, leaving a window of time where there
a reduced level of effectiveness even in patients who
spond to clopidogrel.
.2.3.1.5. Proton Pump Inhibitors and Dual Antiplatelet
herapy for ACS. Proton pump inhibitor (PPI) medica-
ons have been found to interfere with the metabolism of
opidogrel. When clopidogrel is started, PPIs are often
escribed prophylactically to prevent gastrointestinal (GI)
mplications such as ulceration and related bleeding (34)
e to dual antiplatelet therapy, in particular aspirin and
opidogrel (17). Coupled with concern about the GI precau-
ons, there has been increased emphasis on the prevention of
emature discontinuation of dual antiplatelet therapy, partic-
arly in patients who have received a DES for whom 12
onths of antiplatelet therapy is recommended (15).
There have been retrospective reports of adverse cardio-
scular outcomes (e.g., readmission for ACS) when the
tiplatelet regimen of clopidogrel and aspirin is accompa-
ed by PPIs assessed as a group compared with use of this
gimen without a PPI (17,35,36). In a retrospective cohort
udy from the Veterans Affairs’ medical records and phar-
acy database, concomitant clopidogrel and PPI therapy
ith omeprazole, rabeprazole, lansoprazole, or pantopra-
le) at any time during follow-up of 8,205 patients dis-
arged for ACS was associated with an increased risk of
ath or rehospitalization for ACS (17). Other post hoc study
alyses (25) and a retrospective data analysis from the
ational Heart, Lung, and Blood Institute Dynamic Registry,
which PPIs were assessed as a class in combination with a
opidogrel and an aspirin regimen, have not found an effect
PPI therapy on the clinical effect of clopidogrel in ACS
tients, post-ACS patients, and a general post-PCI popula-
on, respectively (25). coSome studies have suggested that adverse cardiovascular
tcomes with the combination of clopidogrel and a PPI are
plained by the individual PPI, in particular, the use of a PPI
at inhibits CYP450 2C19, including omeprazole, lansopra-
le, or rabeprazole. Notably, the PPI omeprazole has been
ported to significantly decrease the inhibitory effect of
opidogrel on platelet aggregation (38,39). One study re-
rted that the PPI pantoprazole was not associated with
current MI among patients receiving clopidogrel, possi-
y due to pantoprazole’s lack of inhibition of CYP450
19 (35).
Other studies have examined the P2Y12 receptor inhibitor
escribed with the PPI. One open-label drug study evaluated
e effects of the PPI lansoprazole on the pharmacokinetics
d pharmacodynamics of prasugrel and clopidogrel in
althy subjects given single doses of prasugrel 60 mg and
opidogrel 300 mg with and without concurrent lansoprazole
mg per day. The data suggest that inhibition of platelet
gregation was reduced in patients who took the combina-
on of clopidogrel and lansoprazole, whereas platelet aggre-
tion was unaffected after a prasugrel dose (40).
Another study (36) assessed the association of PPIs with
e pharmacodynamics and clinical efficacy of clopidogrel
d prasugrel, based on populations from 2 randomized trials,
e PRINCIPLE (Prasugrel In Comparison to Clopidogrel for
hibition of Platelet Activation and Aggregation) TIMI-44
ial (41) and the TRITON–TIMI 38 trial (7). The findings
dicated that first, PPI treatment attenuated the pharmacody-
mic effects of clopidogrel and, to a lesser extent, those of
asugrel. Second, PPI treatment did not affect the clinical
tcome of patients given clopidogrel or prasugrel. This
nding was true for all PPIs that were studied, including
eprazole and pantoprazole.
Observational trials may be confounded by selection bias.
the COGENT (Clopidogrel and the Optimization of Gas-
ointestinal Events) study (42), omeprazole was compared
ith placebo in 3,627 patients starting dual antiplatelet
erapy with aspirin and clopidogrel. No difference was found
the primary composite cardiovascular endpoint between
opidogrel plus omeprazole and clopidogrel plus placebo
R: 1.02), but GI bleeding complications were reduced (42).
OGENT had several shortcomings (see Online Data Sup-
ement), and more controlled, randomized clinical trial data
e needed to address the clinical impact of conjunctive
erapy with clopidogrel and PPIs.
The FDA communication on an ongoing safety review of
opidogrel bisulfate (14) advises that healthcare providers
ould reevaluate the need for starting or continuing treat-
ent with a PPI, including omeprazole, in patients taking
opidogrel. The FDA notes there is no evidence that other
ugs that reduce stomach acid, such as H2 blockers or
tacids, interfere with the antiplatelet activity of clopidogrel.
ealthcare providers should continue to prescribe and pa-
ents should continue to take clopidogrel as directed, because
opidogrel has demonstrated benefits in preventing blood
ots that could lead to a heart attack or stroke. Healthcare
oviders should reevaluate the need for starting or continu-
g treatment with a PPI, including omeprazole (over the
unter), in patients taking clopidogrel. Patients taking clopi-
do
cu
om
us
co
ap
an
cl
3
T
ha
pa
pa
th
(4
us
es
an
N
II
as
N
an
an
T
se
G
U
de
th
pr
of
tin
an
in
in
S
ea
ep
is
pa
9,
is
st
pr
so
hi
le
S
ki
st
re
(d
pr
in
gr
th
P
ho
fo
at
if
pa
of
of
bo
in
ra
de
ti
pa
th
95
ca
ve
E
a
p
G
O
co
p
6.
re
ti
in
se
ad
w
et
(5
II
un
w
ti
it
bi
en
bi
ra
it
th

P
be
th
in
an
is
th
bl
up
655JACC Vol. 60, No. 7, 2012 Jneid et al.
August 14, 2012:645–81 2012 UA/NSTEMI Focused Updategrel should consult their healthcare provider if they are
rrently taking or considering taking a PPI, including
eprazole (14). The ACCF has released a statement on the
e of PPI agents in combination with clopidogrel. The expert
nsensus statement does not prohibit the use of PPI agents in
propriate clinical settings, yet highlights the potential risks
d benefits from use of PPI agents in combination with
opidogrel (43).
.2.3.1.6. Glycoprotein IIb/IIIa Receptor Antagonists.
he efficacy of glycoprotein (GP) IIb/IIIa inhibitor therapy
s been well established during PCI procedures and in
tients with UA/NSTEMI, particularly among high-risk
tients such as those with elevated troponin biomarkers,
ose with diabetes, and those undergoing revascularization
4–54). The preponderance of the evidence supporting the
e of GP IIb/IIIa inhibitor therapy predated the trials that
tablished the benefits of clopidogrel, early invasive therapy,
d contemporary medical treatments in patients with UA/
STEMI. These studies supported the upstream use of a GP
b/IIIa inhibitor as a second agent in combination with
pirin for dual antiplatelet therapy in patients with UA/
STEMI, especially in high-risk subsets such as those with
initial elevation in cardiac troponins, those with diabetes,
d in those undergoing revascularization (47,48,50–52,55).
hese studies did not directly test in a randomized fashion the
lection of an oral thienopyridine versus an intravenous (IV)
P IIb/IIIa inhibitor as the second antiplatelet agent in
A/NSTEMI.
Contemporary clinical trials have therefore been needed to
fine the optimal timing of initiation of GP IIb/IIIa inhibitor
erapy in patients with UA/NSTEMI, whether “upstream” (at
esentation and before angiography) or “deferred” (at the time
angiography/PCI), and its optimal application (whether rou-
e, selective, or provisional) and to clarify the relative benefit
d risk of GP IIb/IIIa inhibitor therapy as a third antiplatelet agent
combination with aspirin and a thienopyridine.
The EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition
Patients With Non–ST-Segment Elevation Acute Coronary
yndrome) trial (56) tested the hypothesis that a strategy of
rly routine administration of the GP IIb/IIIa inhibitor
tifibatide would be superior to delayed provisional admin-
tration in reducing ischemic complications among high-risk
tients with UA/NSTEMI. The study investigators enrolled
492 patients who presented within 24 hours of an episode of
chemic rest discomfort of at least 10 minutes’ duration. The
udy subjects were randomized within 8 to 12 hours after
esentation and assigned to an invasive treatment strategy no
oner than the next calendar day. To qualify as having
gh-risk UA/NSTEMI, the subjects were required to have at
ast 2 of the following: ST-segment depression or transient
T-segment elevation, elevated biomarker levels (creatine
nase–myocardial band or troponin), or age 60 years. The
udy subjects were randomized in a double-blind design to
ceive either early routine administration of eptifibatide
ouble bolus followed by standard infusion) or delayed
ovisional eptifibatide at the time of PCI. Eptifibatide
fusion was given for 18 to 24 hours after PCI in both
oups. For patients who underwent PCI, the total duration of ane infusion was 96 hours. For patients who did not receive
CI for whatever reason, the duration of infusion was 96
urs. The study infusion was stopped 2 hours before surgery
r those undergoing CABG. Early clopidogrel was allowed
the investigators’ discretion (75% intended early use), and
used, a loading dose of 300 mg was recommended. For
tients beginning clopidogrel during PCI (intended in 25%
study subjects, but actually implemented in 11%), a dose
600 mg was permitted. Randomization to 1 of 3 antithrom-
tic regimens was stratified according to the intention of the
vestigator to administer early clopidogrel (i.e., at or before
ndomization) (56).
The primary endpoint (a 30-day composite of all-cause
ath, MI, recurrent ischemia requiring urgent revasculariza-
on, or thrombotic bailout at 96 hours) occurred in 9.3% of
tients in the early therapy arm versus 10.0% of patients in
e provisional GP IIb/IIIa inhibitor therapy arm (OR: 0.92;
% CI: 0.80 to 1.06; p0.23). Secondary endpoint (all-
use death or MI within 30 days) event rates were 11.2%
rsus 12.3% (OR: 0.89; 95% CI: 0.79 to 1.01; p0.08).
arly routine eptifibatide administration was associated with
greater risk of TIMI major hemorrhage (2.6% versus 1.8%;
0.02). Severe or moderate bleeding, as defined by the
USTO (Global Utilization of Streptokinase and t-PA for
ccluded Coronary Arteries) criteria, also occurred more
mmonly in the early eptifibatide group (7.6% versus 5.1%;
0.001). Rates of red blood cell transfusion were 8.6% and
7% in the early-eptifibatide and delayed-eptifibatide groups,
spectively (p0.001). There were no significant interac-
ons with respect to prespecified baseline characteristics,
cluding early clopidogrel administration, and the primary or
condary efficacy endpoints. In a subgroup analysis, early
ministration of eptifibatide in patients who underwent PCI
as associated with numerically fewer ischemic events.
A second contemporary study, the ACUITY (Acute Cath-
erization and Urgent Intervention Triage Strategy) trial
7), examined in part the optimal strategy for the use of GP
b/IIIa inhibitors in moderate- and high-risk ACS patients
dergoing early invasive therapy. A total of 9,207 patients
ere randomized to 1 of 3 antithrombin regimens: unfrac-
onated heparin (UFH) or enoxaparin plus GP IIb/IIIa inhib-
or therapy; bivalirudin plus GP IIb/IIIa inhibitor therapy; or
valirudin alone. Patients assigned to the heparin (UFH or
oxaparin) plus GP IIb/IIIa inhibitor therapy or to the
valirudin plus GP IIb/IIIa inhibitor therapy were also
ndomized to immediate upstream routine GP IIb/IIIa inhib-
or therapy or deferred selective use of GP IIb/IIIa inhibitor
erapy at the time of PCI. A clopidogrel loading dose of
300 mg was required in all cases no later than 2 hours after
CI, and provisional GP IIb/IIIa inhibitor use was permitted
fore angiography in the deferred group for severe break-
rough ischemia. The composite ischemic endpoint occurred
7.1% of the patients assigned to upstream administration
d in 7.9% of patients assigned to deferred selective admin-
tration (RR: 1.12; 95% CI: 0.97 to 1.29; p0.13) (57), and
us the noninferiority hypothesis was not achieved. Major
eeding was lower in the deferred-use group versus the
stream group (4.9% to 6.1%; p0.001 for noninferiority
d p0.009 for superiority).
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2012 UA/NSTEMI Focused Update August 14, 2012:645–81Although early GP IIb/IIIa inhibitor therapy as dual anti-
atelet therapy also reduced complications after PCI, sup-
rting its continued role in patients undergoing PCI
9,53,54,56,58), these 2 most recent studies (56,57) more
rongly support a strategy of selective rather than routine
stream use of GP IIb/IIIa inhibitor therapy as part of triple
tiplatelet therapy. Data from EARLY ACS (56) highlight
e potential bleeding risks of upstream use of a GP IIb/IIIa
hibitor as part of triple antiplatelet therapy. The use of a GP
b/IIIa inhibitor should be undertaken when the risk-benefit
tio suggests a potential benefit for the patient. The use of
ese agents as part of triple antiplatelet therapy may
erefore not be supported when there is a concern for
creased bleeding risk or in non– high-risk subsets such as
ose with a normal baseline troponin level, those without
abetes, and those aged 75 years, in whom the potential
nefit may be significantly offset by the potential risk of
eeding (Tables 2 and 3).
.3. Initial Invasive Versus Initial
onservative Strategies: Recommendations
ee Table 4, and Appendixes 5 and 6 for supplemental
formation.)
.3.3.1. Timing of Invasive Therapy
mong initially stabilized patients with UA/NSTEMI for
hom an early invasive strategy of coronary angiography is
osen, optimal timing of angiography has not been well
fined. Early or immediate catheterization with revascular-
ation of unstable coronary lesions may prevent ischemic
ents that would otherwise occur during medical therapy.
onversely, pretreatment with intensive antithrombotic ther-
y may diminish thrombus burden and “passivate” unstable
aques, improving the safety of percutaneous revasculariza-
on and reducing the risk of periprocedural ischemic com-
ications. Three trials have compared different strategies of
arly” versus “delayed” intervention in patients with UA/
STEMI and form the basis of the updated recommendations
this guideline.
The ISAR-COOL (Intracoronary Stenting with Antithrom-
tic Regimen Cooling-Off) trial (122) carried out at 2
spitals between 2000 and 2002 randomized 410 patients
ith unstable chest pain and either electrocardiographic
T-segment depression or elevated troponin levels to undergo
ronary angiography within 6 hours of presentation (median
4 hours) or after 3 to 5 days (median 86 hours) of
tithrombotic pretreatment (122). Patients with “large MI,”
fined by ST-segment elevation or creatine kinase–
yocardial band isoenzyme activity 3 times normal, were
cluded. Underlying medical therapy in both treatment arms
cluded aspirin, clopidogrel, UFH, and tirofiban. By 30
ys’ follow-up, the primary endpoint of death or large MI
efined by new electrocardiographic Q waves, left bundle-
anch block, or creatine kinase–myocardial band elevation
5 times normal) occurred in 11.6% of patients randomized
delayed catheterization versus 5.9% of those in the early
giography group (p0.04). Differences between treatment
oups were observed exclusively in the period before cath-
erization, with identical event rates in the 2 arms after isgiography. Although providing evidence that a strategy
“cooling-off” for 3 to 5 days before angiography does
t improve outcome in this setting, the findings of this
ial were limited because of the small sample size and the
olonged delay before angiography in the medical pre-
eatment arm.
Information more relevant to contemporary practice pat-
rns was provided in the 2009 publication of the large-scale
ulticenter TIMACS (Timing of Intervention in Acute Cor-
ary Syndromes) trial (107), which compared early versus
layed angiography and intervention in patients with non–
T-segment elevation ACS. Patients were included if they
esented within 24 hours of onset of unstable ischemic
mptoms with advanced age (60 years), elevated cardiac
omarkers, or ischemic electrocardiographic changes, and
ere randomized to undergo angiography as rapidly as
ssible and within 24 hours of randomization (median 14
urs) versus after a minimum delay of 36 hours (median 50
urs). Anticoagulation included aspirin, clopidogrel in
80% of patients, heparin or fondaparinux, and GP IIb/IIIa
hibitors in 23% of patients. Although the trial was initially
wered for enrollment of 4,000 patients to detect a 25%
duction in the primary endpoint of death, new MI, or stroke
6 months, the steering committee chose to terminate
rollment at 3,031 patients because of recruitment chal-
nges. Among the overall trial population, there was only a
nsignificant trend toward a reduced incidence of the pri-
ary clinical endpoint, from 11.3% in the delayed interven-
on group to 9.6% in the early intervention arm (HR for early
tervention: 0.85; 95% CI: 0.68 to 1.06; p0.15). However,
prospectively defined secondary endpoint of death, MI, or
fractory ischemia was significantly reduced by early inter-
ntion from 12.9% to 9.5% (HR: 0.72; 95% CI: 0.58 to 0.89;
0.003), mainly because of a difference in the incidence of
fractory ischemia (3.3% versus 1.0% in the delayed versus
rly intervention arms, respectively; p0.001). The occur-
nce of refractory ischemia was associated with a 4-fold
crease in risk of subsequent MI. Moreover, significant
terogeneity was observed in the primary endpoint when
ratified according to a prespecified estimation of baseline
sk according to the GRACE (Global Registry of Acute
oronary Events) score. Patients in the highest tertile of the
RACE risk score (140) experienced a sizeable and sig-
ficant reduction in the incidence of the primary ischemic
dpoint, from 21.0% to 13.9% (HR: 0.65; 95% CI: 0.48 to
89; p0.006), whereas no difference in outcome (6.7%
rsus 7.6% in the delayed and early groups, respectively;
R: 1.12; 95% CI: 0.81 to 1.56; p0.48) was observed
ong patients in the lower 2 risk tertiles (GRACE score
140) (107).
Results of the TIMACS trial suggested superior outcome
ong patients managed by early rather than delayed inter-
ntion in the setting of UA/NSTEMI, although the reduction
the primary endpoint did not reach statistical significance
r the overall trial population. Nevertheless, refractory isch-
ia was reduced by an early approach, as were the risks of
ath, MI, and stroke among patients at the highest tertile of
chemic risk as defined by the GRACE risk score (107).
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August 14, 2012:645–81 2012 UA/NSTEMI Focused Updateble 2. Recommendations for Antiplatelet Therapy
2012 Focused Update Recommendations 2012 Comments
ass I
1. Aspirin should be administered to UA/NSTEMI patients as soon as possible after hospital presentation and continued
indefinitely in patients who tolerate it (59–66). (Level of Evidence: A)
2011 recommendation remains
current.
2. A loading dose followed by daily maintenance dose of either clopidogrel (13,67,68) (Level of Evidence: B), prasugrel*
(in PCI-treated patients) (7) (Level of Evidence: C), or ticagrelor† (9) (Level of Evidence: C) should be administered to
UA/NSTEMI patients who are unable to take aspirin because of hypersensitivity or major GI intolerance.
2011 recommendation
modified (included prasugrel
and ticagrelor).
3. Patients with definite UA/NSTEMI at medium or high risk and in whom an initial invasive strategy is selected (Appendix 6)
should receive dual antiplatelet therapy on presentation (13,16,45,69). (Level of Evidence: A) Aspirin should be initiated
on presentation (59,61–66). (Level of Evidence: A) The choice of a second antiplatelet therapy to be added to aspirin on
presentation includes 1 of the following (note that there are no data for therapy with 2 concurrent P2Y12 receptor
inhibitors, and this is not recommended in the case of aspirin allergy):
2011 recommendation
modified (included ticagrelor).
Before PCI:
● Clopidogrel (13,16) (Level of Evidence: B); or
● Ticagrelor† (9) (Level of Evidence: B); or
● An IV GP IIb/IIIa inhibitor (45,50,51,70,71). (Level of Evidence: A) IV eptifibatide and tirofiban are the preferred
GP IIb/IIIa inhibitors (50,51). (Level of Evidence: B)
At the time of PCI:
● Clopidogrel if not started before PCI (13,16) (Level of Evidence: A); or
● Prasugrel* (7) (Level of Evidence: B); or
● Ticagrelor† (9) (Level of Evidence: B); or
● An IV GP IIb/IIIa inhibitor (46,50,51). (Level of Evidence: A)
4. For UA/NSTEMI patients in whom an initial conservative (i.e., noninvasive) strategy is selected, clopidogrel or ticagrelor†
(loading dose followed by daily maintenance dose) should be added to aspirin and anticoagulant therapy as soon as
possible after admission and administered for up to 12 months (9,10,13). (Level of Evidence: B)
2011 recommendation
modified (included ticagrelor
and changed duration of
therapy to “up to 12 months”).
5. For UA/NSTEMI patients in whom an initial conservative strategy is selected, if recurrent symptoms/ischemia, heart
failure, or serious arrhythmias subsequently appear, then diagnostic angiography should be performed (55,72). (Level of
Evidence: A) Either an IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban (46,50,51) [Level of Evidence: A]), clopidogrel
(loading dose followed by daily maintenance dose (13) [Level of Evidence: B]), or ticagrelor† (loading dose followed by
daily maintenance dose (9) [Level of Evidence: B]) should be added to aspirin and anticoagulant therapy before
diagnostic angiography (upstream). (Level of Evidence: C)
2011 recommendation
modified (included ticagrelor).
6. A loading dose of P2Y12 receptor inhibitor therapy is recommended for UA/NSTEMI patients for whom PCI is planned.‡
One of the following regimens should be used:
2011 recommendation
modified (included ticagrelor
and changed loading dose of
clopidogrel and associated
level of evidence to be
concordant with 2011 PCI
guideline [75]).
a. Clopidogrel 600 mg should be given as early as possible before or at the time of PCI (32,73,74) (Level of Evidence: B) or
b. Prasugrel* 60 mg should be given promptly and no later than 1 hour after PCI once coronary anatomy is defined and
a decision is made to proceed with PCI (7) (Level of Evidence: B) or
c. Ticagrelor† 180 mg should be given as early as possible before or at the time of PCI (9). (Level of Evidence: B)
7. The duration and maintenance dose of P2Y12 receptor inhibitor therapy should be as follows: 2011 recommendation
modified (included ticagrelor;
a footnote added pertaining to
recommended aspirin
maintenance dose).
a. In UA/NSTEMI patients undergoing PCI, either clopidogrel 75 mg daily (13,16), prasugrel* 10 mg daily (7), or
ticagrelor†
90 mg twice daily (9) should be given for at least 12 months. (Level of Evidence: B)
b. If the risk of morbidity because of bleeding outweighs the anticipated benefits afforded by P2Y12 receptor inhibitor
therapy, earlier discontinuation should be considered. (Level of Evidence: C)
ass IIa
1. For UA/NSTEMI patients in whom an initial conservative strategy is selected and who have recurrent ischemic discomfort
with aspirin, a P2Y12 receptor inhibitor (clopidogrel or ticagrelor), and anticoagulant therapy, it is reasonable to add a
GP IIb/IIIa inhibitor before diagnostic angiography. (Level of Evidence: C)
2007 recommendation
modified (“clopidogrel”
replaced with “P2Y12” receptor
inhibitor [clopidogrel or
ticagrelor]).
2. For UA/NSTEMI patients in whom an initial invasive strategy is selected, it is reasonable to omit administration of an IV
GP IIb/IIIa inhibitor if bivalirudin is selected as the anticoagulant and at least 300 mg of clopidogrel was administered at
least 6 hours earlier than planned catheterization or PCI (57,76,77). (Level of Evidence: B)
2011 recommendation remains
current.(Continued)
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2012 UA/NSTEMI Focused Update August 14, 2012:645–81To assess whether a more aggressive strategy of very early
tervention, analogous to the standard of primary PCI for
TEMI, would lead to improved outcomes in patients with
n–ST-elevation ACS, the ABOARD (Angioplasty to Blunt
e Rise of Troponin in Acute Coronary Syndromes) study
vestigators (123) compared angiography and intervention
rformed immediately on presentation with intervention
rried out on the next working day. A total of 352 patients
ith unstable ischemic symptoms, ECG changes, or troponin
evation were randomized at 13 hospitals to immediate (at a
edian 70 minutes after enrollment) versus delayed (at a
edian 21 hours) angiography and revascularization. Back-
ound antithrombotic therapy consisted of aspirin, clopi-
grel with a loading dose of 300 mg, abciximab during
CI, and the anticoagulant of the investigator’s choice. The
imary trial endpoint was peak troponin I value during the
spitalization period. Immediate intervention conferred no
ble 2. Continued
2012 Focused Update Recommenda
ass IIb
1. For UA/NSTEMI patients in whom an initial conservative (i.e., noninvasive)
add eptifibatide or tirofiban to anticoagulant and oral antiplatelet therapy
2. Prasugrel* 60 mg may be considered for administration promptly upon pr
whom PCI is planned, before definition of coronary anatomy if both the ri
considered unlikely (7,8,78). (Level of Evidence: C)
3. The use of upstream GP IIb/IIIa inhibitors may be considered in high-risk
and a P2Y12 receptor inhibitor (clopidogrel or ticagrelor) who are selected
elevated troponin levels, diabetes, or significant ST-segment depression, a
bleeding (50,51,55,56,58). (Level of Evidence: B)
4. In patients with definite UA/NSTEMI undergoing PCI as part of an early in
clopidogrel of 600 mg, followed by a higher maintenance dose of 150 mg
reasonable in patients not considered at high risk for bleeding (32). (Leve
ass III: No Benefit
1. Abciximab should not be administered to patients in whom PCI is not pla
2. In UA/NSTEMI patients who are at low risk for ischemic events (e.g., TIM
who are already receiving aspirin and a P2Y12 receptor inhibitor, upstream
(56,57,78). (Level of Evidence: B)
ass III: Harm
1. In UA/NSTEMI patients with a prior history of stroke and/or TIA for whom
harmful as part of a dual antiplatelet therapy regimen (7). (Level of Eviden
*Patients weighing60 kg have an increased exposure to the active metaboli
se. Consideration should be given to lowering the maintenance dose to 5 mg
se have not been studied prospectively. For post-PCI patients, a daily mainten
12 months for patients receiving BMS unless the risk of bleeding outweighs th
patients with active pathological bleeding or a history of TIA or stroke. In patien
k of fatal and intracranial bleeding and uncertain benefit except in high-risk s
effect appears to be greater and its use may be considered. Do not start prasu
least 7 days before any surgery (8). Additional risk factors for bleeding include
crease the risk of bleeding (e.g., warfarin, heparin, fibrinolytic therapy, or chr
†The recommended maintenance dose of aspirin to be used with ticagrelor i
ith clopidogrel (9). When possible, discontinue ticagrelor at least 5 days be
nsideration should be given to the potential and as yet undetermined risk of
‡Applies to patients who were not treated chronically with these medication
BMS indicates bare-metal stent; CABG, coronary artery bypass graft; DE
rcutaneous coronary intervention; TIA, transient ischemic attack; TIMI, Throm
yocardial infarction.vantage with regard to the primary endpoint (median hooponin I value 2.1 versus 1.7 ng/mL in the immediate and
layed intervention groups, respectively), nor was there
en a trend toward improved outcome in the prespecified
inical secondary endpoint of death, MI, or urgent revascu-
rization by 1 month (13.7% versus 10.2% in the immediate
d delayed intervention groups, respectively; p0.31) (123).
These 3 trials (107,122,123), taken together with earlier
udies, do provide support for a strategy of early angiogra-
y and intervention to reduce ischemic complications in
tients who have been selected for an initial invasive
rategy, particularly among those at high risk (defined by a
RACE score 140), whereas a more delayed approach is
asonable in low- to intermediate-risk patients. The “early”
me period in this context is considered to be within the first
hours after hospital presentation, although there is no
idence that incremental benefit is derived by angiography
d intervention performed within the first few hours of
2012 Comments
y is selected, it may be reasonable to
(Level of Evidence: B)
2007 recommendation remains
current.
on in patients with UA/NSTEMI for
eeding is low and the need for CABG is
2011 recommendation remains
current.
EMI patients already receiving aspirin
nvasive strategy, such as those with
are not otherwise at high risk for
2011 recommendation
modified (“clopidogrel”
replaced with “P2Y12” receptor
inhibitor [clopidogrel or
ticagrelor]).
trategy, the use of a loading dose of
or 6 days, then 75 mg daily may be
ence: B)
2011 recommendation remains
current.
,71). (Level of Evidence: A) 2007 recommendation remains
current.
ore 2) or at high risk of bleeding and
/IIIa inhibitors are not recommended
2011 recommendation
modified (“clopidogrel”
replaced with “P2Y12 receptor
inhibitor”).
lanned, prasugrel* is potentially 2011 recommendation remains
current.
sugrel and an increased risk of bleeding on a 10-mg once-daily maintenance
nts who weigh 60 kg, although the effectiveness and safety of the 5-mg
se should be given for at least 12 months for patients receiving DES and up
ated net benefit afforded by a P2Y12 receptor inhibitor. Do not use prasugrel
75 years, prasugrel is generally not recommended because of the increased
(patients with diabetes or a history of prior myocardial infarction), in which
atients likely to undergo urgent CABG. When possible, discontinue prasugrel
eight 60 kg, propensity to bleed, and concomitant use of medications that
of nonsteroidal anti-inflammatory drugs) (8).
daily (11). Ticagrelor’s benefits were observed irrespective of prior therapy
surgery (12). Issues of patient compliance may be especially important.
nial hemorrhage in patients with prior stroke or TIA.
eluting stent; GI, gastrointestinal; GP, glycoprotein; IV, intravenous; PCI,
In Myocardial Infarction; and UA/NSTEMI, unstable angina/non–ST-elevationtions
strateg
(50,51).
esentati
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UA/NST
for an i
nd who
vasive s
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August 14, 2012:645–81 2012 UA/NSTEMI Focused Updateble 3. Recommendations for Additional Management of Antiplatelets and Anticoagulants
2012 Focused Update Recommendations 2012 Comments
ass I
1. For UA/NSTEMI patients in whom an initial conservative strategy is selected and no subsequent features appear that
would necessitate diagnostic angiography (recurrent symptoms/ischemia, heart failure, or serious arrhythmias), a stress
test should be performed (72). (Level of Evidence: B)
2011 recommendation
modified (included ticagrelor,
and duration of antiplatelet
therapy changed to “up to
12 months”).
a. If, after stress testing, the patient is classified as not at low risk, diagnostic angiography should be performed (55,72).
(Level of Evidence: A)
b. If, after stress testing, the patient is classified as being at low risk, the instructions noted below should be followed in
preparation for discharge (55,72):
1. Continue aspirin indefinitely (61,63,64). (Level of Evidence: A)
2. Continue clopidogrel or ticagrelor* for up to 12 months (9,10,13). (Level of Evidence: B)
3. Discontinue IV GP IIb/IIIa inhibitor if started previously (50,51). (Level of Evidence: A)
4. Continue UFH for 48 hours (66,79) (Level of Evidence: A) or administer enoxaparin (80–82) (Level of Evidence: A) or
fondaparinux (83) (Level of Evidence: B) for the duration of hospitalization, up to 8 days, and then discontinue
anticoagulant therapy.
2. For UA/NSTEMI patients in whom CABG is selected as a postangiography management strategy, the instructions noted
below should be followed.
2011 recommendation remains
current.
a. Continue aspirin (84–90). (Level of Evidence: A)
b. See Class I, #3, in this section.
c. Discontinue IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban) 4 hours before CABG (84,88,91). (Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
1. Continue UFH (80,92–94). (Level of Evidence: B)
2. Discontinue enoxaparin 12 to 24 hours before CABG and dose with UFH per institutional practice (80,92–94).
(Level of Evidence: B)
3. Discontinue fondaparinux 24 hours before CABG and dose with UFH per institutional practice (95,96).
(Level of Evidence: B)
4. Discontinue bivalirudin 3 hours before CABG and dose with UFH per institutional practice (97,98). (Level of
Evidence: B)
3. In patients taking a P2Y12 receptor inhibitor in whom CABG is planned and can be delayed, it is recommended that the
drug be discontinued to allow for dissipation of the antiplatelet effect (13) (Level of Evidence: B). The period of
withdrawal should be at least 5 days in patients receiving clopidogrel (13,45,99) (Level of Evidence: B) or ticagrelor* (12)
(Level of Evidence: C) and at least 7 days in patients receiving prasugrel† (8) (Level of Evidence: C) unless the need for
revascularization and/or the net benefit of the P2Y12 receptor inhibitor therapy outweighs the potential risks of excess
bleeding (100). (Level of Evidence: C)
2011 recommendation
modified (included ticagrelor).
4. For UA/NSTEMI patients in whom PCI has been selected as a postangiography management strategy, the instructions
noted below should be followed:
2011 recommendation
modified (“thienopyridine”
replaced with “P2Y12 receptor
inhibitor”).
a. Continue aspirin (61,63,64). (Level of Evidence: A)
b. Administer a loading dose of a P2Y12 receptor inhibitor if not started before diagnostic angiography (9,68,74,101–103).
(Level of Evidence: A)
c. Discontinue anticoagulant therapy after PCI for uncomplicated cases (80,82,104–106). (Level of Evidence: B)
5. For UA/NSTEMI patients in whom medical therapy is selected as a management strategy and in whom no significant
obstructive coronary artery disease on angiography was found, antiplatelet and anticoagulant therapy should be
administered at the discretion of the clinician (Level of Evidence: C). For patients in whom evidence of coronary
atherosclerosis is present (e.g., luminal irregularities or intravascular ultrasound-demonstrated lesions), albeit without
flow-limiting stenoses, long-term treatment with aspirin and other secondary prevention measures should be prescribed.
(Level of Evidence: C)
2007 recommendation remains
current.
6. For UA/NSTEMI patients in whom medical therapy is selected as a management strategy and in whom coronary artery
disease was found on angiography, the following approach is recommended:
2011 recommendation
modified (included ticagrelor).
a. Continue aspirin (61,63,64). (Level of Evidence: A)
b. Administer a loading dose of clopidogrel or ticagrelor* if not given before diagnostic angiography (9,13).
(Level of Evidence: B)
c. Discontinue IV GP IIb/IIIa inhibitor if started previously (50,51,57,107). (Level of Evidence: B)(Continued)
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2012 Focused Update Recommendations 2012 Comments
d. Anticoagulant therapy should be managed as follows:
1. Continue IV UFH for at least 48 hours or until discharge if given before diagnostic angiography (66,79,80)
(Level of Evidence: A)
2. Continue enoxaparin for duration of hospitalization, up to 8 days, if given before diagnostic angiography (80–82,96).
(Level of Evidence: A)
3. Continue fondaparinux for duration of hospitalization, up to 8 days, if given before diagnostic angiography (83).
(Level of Evidence: B)
4. Either discontinue bivalirudin or continue at a dose of 0.25 mg/kg per hour for up to 72 hours at the physician’s
discretion if given before diagnostic angiography (77,108,109). (Level of Evidence: B)
7. For UA/NSTEMI patients in whom a conservative strategy is selected and who do not undergo angiography or stress
testing, the instructions noted below should be followed:
2011 recommendation modified
(included ticagrelor; duration of
antiplatelet therapy changed to
“up to 12 months”).
a. Continue aspirin indefinitely (61,63,64). (Level of Evidence: A)
b. Continue clopidogrel or ticagrelor* for up to 12 months (9,13,67,110). (Level of Evidence: B)
c. Discontinue IV GP IIb/IIIa inhibitor if started previously (50,51). (Level of Evidence: A)
d. Continue UFH for 48 hours (66,79) (Level of Evidence: A) or administer enoxaparin (80–82) (Level of Evidence: A) or
fondaparinux (83) (Level of Evidence: B) for the duration of hospitalization, up to 8 days, and then discontinue
anticoagulant therapy.
8. For UA/NSTEMI patients in whom an initial conservative strategy is selected and in whom no subsequent features appear
that would necessitate diagnostic angiography (recurrent symptoms/ischemia, heart failure, or serious arrhythmias),
LVEF should be measured (55,111–114). (Level of Evidence: B)
2007 recommendation remains
current.
ass IIa
1. For UA/NSTEMI patients in whom PCI has been selected as a postangiography management strategy, it is reasonable to
administer an IV GP IIb/IIIa inhibitor (abciximab, eptifibatide, or tirofiban) if not started before diagnostic angiography,
particularly for troponin-positive and/or other high-risk patients (55,58). (Level of Evidence: A)
2011 recommendation remains
current.
2. For UA/NSTEMI patients in whom PCI is selected as a management strategy, it is reasonable to omit administration of an
IV GP IIb/IIIa inhibitor if bivalirudin was selected as the anticoagulant and at least 300 mg of clopidogrel was
administered at least 6 hours earlier (55,57). (Level of Evidence: B)
2007 recommendation remains
current.
3. If LVEF is less than or equal to 0.40, it is reasonable to perform diagnostic angiography (111–114). (Level of Evidence: B) 2007 recommendation remains
current.
4. If LVEF is greater than 0.40, it is reasonable to perform a stress test (111). (Level of Evidence: B) 2007 recommendation remains
current.
ass IIb
1. Platelet function testing to determine platelet inhibitory response in patients with UA/NSTEMI (or, after ACS and PCI) on
P2Y12 receptor inhibitor therapy may be considered if results of testing may alter management (115–119).
(Level of Evidence: B)
2011 recommendation
modified (“thienopyridine”
replaced with “P2Y12 receptor
inhibitor”).
2. Genotyping for a CYP2C19 loss of function variant in patients with UA/NSTEMI (or, after ACS and with PCI) on P2Y12
receptor inhibitor therapy might be considered if results of testing may alter management (19–22,25,27,120).
(Level of Evidence: C)
2011 recommendation
modified (“thienopyridine”
replaced with “P2Y12 receptor
inhibitor”).
ass III: No Benefit
1. IV fibrinolytic therapy is not indicated in patients without acute ST-segment elevation, a true posterior MI, or a presumed
new left bundle-branch block (121). (Level of Evidence: A)
2007 recommendation remains
current.
*The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily (11). The benefits of ticagrelor were observed irrespective of prior therapy
ith clopidogrel (9). When possible, discontinue ticagrelor at least 5 d before any surgery (12). Issues of patient compliance may be especially important. Consideration
ould be given to the potential and as yet undetermined risk of intracranial hemorrhage in patients with prior stroke or TIA.
†Patients weighing60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10-mg once-daily maintenance
se. Consideration should be given to lowering the maintenance dose to 5 mg in patients who weigh 60 kg, although the effectiveness and safety of the 5-mg
se have not been studied prospectively. For post-PCI patients, a daily maintenance dose should be given for at least 12 mo for patients receiving DES and up to
months for patients receiving BMS unless the risk of bleeding outweighs the anticipated net benefit afforded by a P2Y12 receptor inhibitor. Do not use prasugrel
patients with active pathological bleeding or a history of TIA or stroke. In patients age 75 y, prasugrel is generally not recommended because of the increased
k of fatal and intracranial bleeding andrrruncertain benefit except in high-risk situations (patients with diabetes or a history of prior MI), in which its effect appears
be greater and its use may be considered. Do not start prasugrel in patients likely to undergo urgent CABG. When possible, discontinue prasugrel at least 7 d before
y surgery (8). Additional risk factors for bleeding include body weight 60 kg, propensity to bleed, and concomitant use of medications that increase the risk of
eeding (e.g., warfarin, heparin, fibrinolytic therapy, or chronic use of nonsteroidal anti-inflammatory drugs) (8).
ACS indicates acute coronary syndrome; BMS, bare-metal stent; CABG, coronary artery bypass graft; DES, drug-eluting stent; GP, glycoprotein; IV, intravenous;
EF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; UA/NSTEMI, unstable
gina/non–ST-elevation myocardial infarction; and UFH, unfractionated heparin.
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August 14, 2012:645–81 2012 UA/NSTEMI Focused Updatehieved in the context of intensive background antithrom-
tic therapy (Table 4).
. Late Hospital Care,
ospital Discharge, and
osthospital Discharge Care
.2. Long-Term Medical Therapy and
econdary Prevention
.2.1. Convalescent and Long-Term Antiplatelet
herapy: Recommendations
ee Table 5 and Appendix 3 for supplemental information.)
.2.6. Warfarin Therapy: Recommendations
ee Table 6.)
. Special Groups
.2. Diabetes Mellitus: Recommendations
ee Table 7.)
.2.1.1. Intensive Glucose Control
s detailed in the 2004 STEMI guideline (153), 2007
A/NSTEMI guideline revision (4), and 2009 STEMI and
CI focused update (154), randomized trial evidence sup-
rted use of insulin infusion to control hyperglycemia. A
inical trial of intensive versus conventional glucose control
critically ill patients raised uncertainty about the optimal
ble 4. Recommendations for Initial Invasive Versus Initial Con
2012 Focused Update Recommend
ass I
1. An early invasive strategy (i.e., diagnostic angiography with intent to perfo
patients who have refractory angina or hemodynamic or electrical instabil
contraindications to such procedures) (124,125). (Level of Evidence: B)
2. An early invasive strategy (i.e., diagnostic angiography with intent to perfo
stabilized UA/NSTEMI patients (without serious comorbidities or contraindicatio
for clinical events (see 2007 (4) Table 11 and 2007 Sections 2.2.6 and 3.4.3
ass IIa
1. It is reasonable to choose an early invasive strategy (within 12 to 24 hou
for initially stabilized high-risk patients with UA/NSTEMI.* For patients not
reasonable (107). (Level of Evidence: B)
ass IIb
1. In initially stabilized patients, an initially conservative (i.e., a selectively in
treatment strategy for UA/NSTEMI patients (without serious comorbidities
have an elevated risk for clinical events (see 2007 (4) Table 11 and Secti
troponin positive (111,126). (Level of Evidence: B) The decision to implem
strategy in these patients may be made by considering physician and pat
ass III: No Benefit
1. An early invasive strategy (i.e., diagnostic angiography with intent to perfo
patients with extensive comorbidities (e.g., liver or pulmonary failure, can
comorbid conditions are likely to outweigh the benefits of revascularizatio
2. An early invasive strategy (i.e., diagnostic angiography with intent to perfo
patients with acute chest pain and a low likelihood of ACS. (Level of Evid
3. An early invasive strategy (i.e., diagnostic angiography with intent to perfo
patients who will not consent to revascularization regardless of the findin
*Immediate catheterization/angiography is recommended for unstable patienACS indicates acute coronary syndrome; and UA/NSTEMI, unstable angina/non–ST-evel to target when achieving glucose control. NICE-
UGAR (Normoglycaemia in Intensive Care Evaluation–
urvival Using Glucose Algorithm Regulation), a large inter-
tional randomized trial (n6,104) of adults admitted to the
tensive care unit with either medical or surgical conditions,
mpared intensive glucose control (target glucose range, 81
108 mg/dL) with conventional glucose control (to achieve
glucose level of 180 mg/dL, with reduction and discon-
nuation of insulin if the blood glucose level dropped below
4 mg/dL) (149). Time-weighted glucose levels achieved
ere 11518 mg/dL in the intensive group versus 14423
g/dL in the conventional group. The risk of death was
creased at 90 days in the intensive group by 2.6% (27.5%
rsus 24.9%; OR: 1.14; 95% CI: 1.02 to 1.08; p0.02;
mber needed to harm38). The result remained the same
ter adjusting for potential confounders. There were signif-
antly more episodes of treatment-related hypoglycemia in
e intensely managed group (6.8% versus 0.5%; p0.001),
though the contribution of hypoglycemia to excess mor-
lity is uncertain (149,150). Overall, the hospital course
d proximate causes of death were similar in the 2 groups.
xcess deaths in the intensive management group were
edominantly of cardiovascular causes (absolute differ-
ce: 5.8%; p0.02). More patients in the intensive group
an in the conventional group were treated with cortico-
eroids.
Because NICE-SUGAR (149) enrolled critically ill medi-
l and surgical patients, the degree to which its results can be
ve Strategies
2012 Comments
scularization) is indicated in UA/NSTEMI
out serious comorbidities or
2007 recommendation remains
current.
scularization) is indicated in initially
ch procedures) who have an elevated risk
111). (Level of Evidence: A)
2007 recommendation remains
current.
mission) over a delayed invasive strategy
risk, a delayed invasive approach is also
2011 recommendation remains
current.
strategy may be considered as a
aindications to such procedures) who
.6 and 3.4.3), including those who are
nitial conservative (vs. initial invasive)
ference. (Level of Evidence: C)
2007 recommendation remains
current.
scularization) is not recommended in
whom the risks of revascularization and
l of Evidence: C)
2007 recommendation remains
current.
scularization) is not recommended in 2007 recommendation remains
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STEMI is unclear. Although recent data from a small,
ble 5. Recommendations for Convalescent and Long-Term An
2012 Focused Update Recommenda
ass I
1. For UA/NSTEMI patients treated medically without stenting, aspirin* shoul
of Evidence: A); clopidogrel (75 mg per day) or ticagrelor† (90 mg twice d
(9,10,14). (Level of Evidence: B)
2. For UA/NSTEMI patients treated with a stent (BMS or DES), aspirin should be
The duration and maintenance dose of P2Y12 receptor inhibitor therapy sh
a. Clopidogrel 75 mg daily (16), prasugrel‡ 10 mg daily (7), or ticagrelor†
least 12 months in patients receiving DES and up to 12 months for pa
Evidence: B)
b. If the risk of morbidity because of bleeding outweighs the anticipated b
therapy, earlier discontinuation should be considered. (Level of Evidenc
3. Clopidogrel 75 mg daily (13,67) (Level of Evidence: B), prasugrel‡ 10 mg
Evidence: C), or ticagrelor† 90 mg twice daily (9) (Level of Evidence: C) s
UA/NSTEMI when aspirin is contraindicated or not tolerated because of hy
gastroprotective agents such as PPIs) (42,68).
ass IIa
1. After PCI, it is reasonable to use 81 mg per day of aspirin in preference to hi
(Level of Evidence: B)
ass IIb
1. For UA/NSTEMI patients who have an indication for anticoagulation, the a
maintain an INR of 2.0 to 3.0 (129–138). (Level of Evidence: B)
2. Continuation of a P2Y12 receptor inhibitor beyond 12 months may be con
(Level of Evidence: C)
ass III: No Benefit
1. Dipyridamole is not recommended as an antiplatelet agent in post-UA/NST
be effective (90,139,140). (Level of Evidence: B)
*For aspirin-allergic patients, use either clopidogrel or ticagrelor alone (indefi
concurrent P2Y12 receptor inhibitors, and this is not recommended in the cas
†The recommended maintenance dose of aspirin to be used with ticagrelor i
ith clopidogrel (9). When possible, discontinue ticagrelor at least 5 d before any
ould be given to the potential and as yet undetermined risk of intracranial he
‡Patients weighing60 kg have an increased exposure to the active metaboli
se. Consideration should be given to lowering the maintenance dose to 5 mg
se have not been studied prospectively. For post-PCI patients, a daily mainte
mo for patients receiving BMS unless the risk of bleeding outweighs the an
tients with active pathological bleeding or a history of TIA or stroke. In patient
fatal and intracranial bleeding and uncertain benefit except in high-risk situa
fect appears to be greater and its use may be considered. Do not start prasug
least 7 d before any surgery (8). Additional risk factors for bleeding include b
crease the risk of bleeding (e.g., warfarin, heparin, fibrinolytic therapy, or chr
§Continue aspirin indefinitely and warfarin longer term as indicated for specific
boli.
An INR of 2.0 to 2.5 is preferable while given with aspirin and a P2Y12 recept
r UA/NSTEMI patients who have mechanical heart valves, the INR should be
BMS indicates bare-metal stent; CABG, coronary artery bypass graft; DES,
ntricular; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor
yocardial infarction.echanistic clinical trial (155) suggest that glucose control way reduce inflammation and improve left ventricular ejec-
on fraction in patients with acute MI, it remains uncertain
et Therapy
2012 Comments
scribed indefinitely (60,61,63,64) (Level
ould be prescribed for up to 12 months
2011 recommendation
modified (included ticagrelor
and footnote added pertaining
to recommended aspirin
maintenance dose).
d indefinitely. (Level of Evidence: A)
as follows:
2011 recommendation
modified (included the term
“P2Y12 receptor inhibitor” and
altered aspirin dosing and
duration of therapy after stent
deployment).
twice daily (9) should be given for at
ceiving BMS (9,13,16). (Level of
afforded by P2Y12 receptor inhibitor
PCI-treated patients) (7) (Level of
given to patients recovering from
itivity or GI intolerance (despite use of
2011 recommendation
modified (included prasugrel
and ticagrelor; deleted
ticlopidine).
ntenance doses (32,33,90,127,128). 2011 recommendation
modified (changed wording
and aspirin dose to be
concordant with the 2011 PCI
guideline [75]).
f warfarin§ may be reasonable to 2007 recommendation remains
current.
in patients following DES placement. 2011 recommendation
modified (changed time period
to be concordant with 2011
PCI guideline [75] and replaced
“clopidogrel and prasugrel”
with “P2Y12 receptor
inhibitor”).
tients because it has not been shown to 2011 recommendation remains
current.
r try aspirin desensitization. Note that there are no data for therapy with
pirin allergy.
daily (11). Ticagrelor’s benefits were observed irrespective of prior therapy
(12). Issues of patient compliance may be especially important. Consideration
ge in patients with prior stroke or TIA.
sugrel and an increased risk of bleeding on a 10-mg once-daily maintenance
nts who weigh 60 kg, although the effectiveness and safety of the 5-mg
ose should be given for at least 12 mo for patients receiving DES and up to
net benefit afforded by a P2Y12 receptor inhibitor. Do not use prasugrel in
75 y, prasugrel is generally not recommended because of the increased risk
tients with diabetes or a history of prior myocardial infarction), in which its
atients likely to undergo urgent CABG. When possible, discontinue prasugrel
ight 60 kg, propensity to bleed, and concomitant use of medications that
of nonsteroidal anti-inflammatory drugs) (8).
ons such as atrial fibrillation; LV thrombus; or cerebral, venous, or pulmonary
tor, especially in older patients and those with other risk factors for bleeding.
2.5 (based on type of prosthesis).
ting stent; GI, gastrointestinal; INR, international normalized ratio; LV, left
nsient ischemic attack; and UA/NSTEMI, unstable angina/non–ST-elevationtiplatel
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August 14, 2012:645–81 2012 UA/NSTEMI Focused UpdateA consensus statement by the American Association of
linical Endocrinologists and the American Diabetes Asso-
ation (157) summarized that “although hyperglycemia is
sociated with adverse outcomes after acute MI, reduction of
ycemia per se and not necessarily the use of insulin is
sociated with improved outcomes. It remains unclear,
wever, whether hyperglycemia is a marker of underlying
alth status or is a mediator of complications after acute MI.
oniatrogenic hypoglycemia has also been associated with
verse outcomes and is a predictor of higher mortality.”
There is a clear need for a well-designed, definitive
ndomized trial of target-driven glucose control in UA/
STEMI patients with meaningful clinical endpoints so that
ucose treatment thresholds and glucose targets can be
termined. Until such a trial is completed, and on the basis
the balance of current evidence (157–159), the writing
oup concluded that it was prudent to change the recom-
endation for the use of insulin to control blood glucose in
A/NSTEMI from a more stringent to a more moderate
rget range in keeping with the recent 2009 STEMI and PCI
cused update (Class IIa, LOE: B) (154) and recommend
eatment for hyperglycemia 180 mg/dL while avoiding
poglycemia. The writing group believed that the 2007
commendation (4) regarding long-term glycemic control
rgets failed to reflect recent data casting doubt on a specific
ble 6. Recommendations for Warfarin Therapy
2012 Focused Update Recommenda
ass I
1. Use of warfarin in conjunction with aspirin and/or P2Y12 receptor inhibitor
bleeding, and patients and clinicians should watch for bleeding, especially
of bleeding (7,9,13,14,141–144). (Level of Evidence: A)
ass IIb
1. Warfarin either without (INR 2.5 to 3.5) or with low-dose aspirin (81 mg p
patients at high coronary artery disease risk and low bleeding risk who d
inhibitor therapy (145,146). (Level of Evidence: B)
2. Targeting oral anticoagulant therapy to a lower INR (e.g., 2.0 to 2.5) migh
managed with aspirin and a P2Y12 inhibitor. (Level of Evidence: C)
GI indicates gastrointestinal; INR, international normalized ratio; and UA/NST
ble 7. Recommendations for Diabetes Mellitus
2012 Focused Update Recommenda
ass I
1. Medical treatment in the acute phase of UA/NSTEMI and decisions on wh
and revascularization should be similar in patients with and without diabete
ass IIa
1. For patients with UA/NSTEMI and multivessel disease, CABG with use of t
over PCI in patients being treated for diabetes mellitus (148). (Level of Ev
2. PCI is reasonable for UA/NSTEMI patients with diabetes mellitus with sing
(Level of Evidence: B)
3. It is reasonable to use an insulin-based regimen to achieve and maintain
avoiding hypoglycemia* for hospitalized patients with UA/NSTEMI with eith
(149–152). (Level of Evidence: B)
*There is uncertainty about the ideal target range for glucose necessary to aCABG indicates coronary artery bypass graft; PCI, percutaneous coronary interventioneal goal for the management of diabetes in patients with
A/NSTEMI.
Diabetes is another characteristic associated with high risk
r adverse outcomes after UA/NSTEMI. The 2007 UA/
STEMI guidelines (4) state that patients with diabetes are at
gh risk and in general should be treated similarly to patients
ith other high-risk features. However, the 2012 writing
oup noted that diabetes was not listed as a high-risk feature
r which an invasive strategy was specifically preferred, in
ntrast to the inclusion of chronic kidney disease (CKD) and
abetes mellitus as characteristics favoring an invasive
proach in the 2007 European Society of Cardiology
idelines for management of UA/NSTEMI (160). To
visit this question for diabetes, the writing group re-
ewed results of the published analysis of patients with
abetes in the FRISC-II (FRagmin and Fast Revasculariza-
on during InStability in Coronary artery disease) trial (72).
verall, the FRISC-II trial demonstrated a benefit with
vasive management compared with conservative manage-
ent in patients with UA/NSTEMI. There were similar
ductions in the risk of MI/death at 1 year in the diabetic
bgroup randomized to an invasive strategy (OR: 0.61; 95%
I: 0.36 to 1.04) compared with patients who did not have
abetes randomized to an invasive strategy (OR: 0.72; 95%
I: 0.54 to 0.95). The risk of death was also reduced by
2012 Comments
is associated with an increased risk of
seek medical evaluation for evidence
2011 recommendation
modified (“thienopyridine”
replaced with “P2Y12
receptor inhibitor”).
INR 2.0 to 2.5) may be reasonable for
quire or are intolerant of P2Y12 receptor
2011 recommendation
modified (“thienopyridine”
replaced with “P2Y12
receptor inhibitor”).
sonable in patients with UA/NSTEMI New recommendation
table angina/non–ST-elevation myocardial infarction.
2012 Comments
perform stress testing, angiography,
s (55,72,81,147). (Level of Evidence: A)
2007 recommendation remains
current.
nal mammary arteries can be beneficial
B)
2007 recommendation remains
current.
l disease and inducible ischemia (55). 2007 recommendation remains
current.
levels less than 180 mg/dL while
mplicated or uncomplicated course
2011 recommendation remains
current.
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2012 UA/NSTEMI Focused Update August 14, 2012:645–81ndomization to an invasive strategy among patients with
abetes (OR: 0.59; 95% CI: 0.27 to 1.27) and without
abetes (OR: 0.50; 95% CI: 0.27 to 0.94). Subgroup analysis
the TACTICS–TIMI-18 (Treat Angina with aggrastat and
termine Cost of Therapy with Invasive or Conservative
trategy–Thrombolysis In Myocardial Infarction 18) study in
tients with diabetes, available in abstract form, was con-
stent with this finding (161). Thus, diabetes, as well as the
ten concurrent comorbidity of CKD (Section 6.5, Chronic
idney Disease: Recommendations), is not only a high-risk
ctor but also benefits from an invasive approach. Accord-
gly, diabetes has been added to the list of characteristics for
hich an early invasive strategy is generally preferred (Ap-
ndix 6).
.5. Chronic Kidney Disease:
ecommendations
ee Table 8, and Online Data Supplement.)
.5.1. Angiography in Patients With CKD
ince the 2007 UA/NSTEMI Guidelines were published (4),
veral larger randomized trials have been published that
ported no difference in contrast-induced nephropathy (CIN)
hen iodixanol was compared with various other low-
molar contrast media (LOCM) (170–173). These and other
ndomized trials comparing isosmolar iodixanol with
OCM have been summarized in 2 mutually supportive and
mplementary meta-analyses involving 16 trials in 2,763
tients (174) and 25 trials in 3,260 patients (175), respec-
vely. When more recent trials were combined with the older
udies, the data supporting a reduction in CIN favoring
dixanol were no longer significant (summary RR: 0.79;
% CI: 0.56 to 1.12; p0.29 [174]; summary RR: 0.80; 95%
I: 0.61 to 1.04; p0.10 [175], respectively). However,
banalyses showed variations in relative renal safety by
ecific LOCM: A reduction in CIN was observed when
dixanol was compared to ioxaglate, the only ionic LOCM
R: 0.58; 95% CI: 0.37 to 0.92; p0.022 [174]), and to
hexol, a nonionic LOCM (RR: 0.19; 95% CI: 0.07 to 0.56;
0.0002 [174]), but no difference was noted in comparisons
iodixanol with iopamidol, iopromide, or ioversol (174),
d a single trial favored iomeprol (170). A pooled compar-
on of iodixanol with all nonionic LOCM other than iohexol
ble 8. Recommendations for Chronic Kidney Disease
2012 Focused Update Recommenda
ass I
1. Creatinine clearance should be estimated in UA/NSTEMI patients and the
adjusted according to the pharmacokinetic data for specific medications (
2. Patients undergoing cardiac catheterization with receipt of contrast media
(164,165). (Level of Evidence: B)
3. Calculation of the contrast volume to creatinine clearance ratio is useful t
media that can be given without significantly increasing the risk of contra
(Level of Evidence: B)
ass IIa
1. An invasive strategy is reasonable in patients with mild (stage 2) and mo
(Level of Evidence: B) (There are insufficient data on benefit/risk of invasi
advanced CKD [stages 4, 5].)CKD indicates chronic kidney disease; and UA/NSTEMI, unstable angina/non–ST-elevdicated equivalent safety (RR: 0.97; 95% CI: 0.72 to 1.32;
0.86 [175]). Results were consistent regardless of ancil-
ry preventive therapies (hydration, acetylcysteine), route of
ministration (IV or intra-arterial), age, sex, dose, or preex-
ting CKD or diabetes. Of further interest, findings were
milar in the 8 studies (n1,793 patients) performed in the
tting of coronary angiography (174). A more recent study
mparing iodixanol versus iopamidol provides additional
pportive evidence (176). However, even these clinical
ferences must be tempered by the relative paucity of
ad-to-head trials comparing CIN rates among the various
ntrast media and the variability in results (e.g., for iohexol
rsus other low-osmolar comparators) (177–180). Further-
ore, the assumption that a transient rise in serum creatinine
ter 24 to 48 hours is a reliable predictor of the more serious
t somewhat delayed development of renal failure requiring
spitalization or dialysis has been challenged. A nationwide
wedish survey (181) of hospitalizations for renal failure
ter coronary procedures in 57,925 patients found that this
sk was paradoxically higher with iodixanol (1.7%) than
xaglate (0.8%) or iohexol (0.9%; p0.001). Although the
sult was observational, hence subject to selection bias, it
rsisted in analyses of high-risk patient subsets (patients
ith diabetes, prior history of renal failure), in multivariable
alysis, and in hospitals crossing over from ioxaglate to
dixanol. Iodixanol’s greater viscosity was speculated but
t demonstrated to be a possible mechanism for the ob-
rved effect. Thus, an overall summary of the current
tabase, updated since previous guideline recommendations
), is that strength and consistency of relationships between
ecific isosmolar or low-osmolar agents and CIN or renal
ilure are not sufficient to enable a guideline statement on
lection among commonly used low-osmolar and isosmolar
edia. Instead, the writing group recommends focusing on
erator conduct issues shown to be important to protect
tients, that is, 1) proper patient preparation with hydration,
d 2) adjustment of maximal contrast dose to each patient’s
nal function and other clinical characteristics.
With respect to patient preparation, the writing group
viewed several trials addressing the optimal preparatory
gimen of hydration and pharmacotherapy. The basic prin-
ple of hydration follows from experimental studies and
2012 Comments
f renally cleared medications should be
). (Level of Evidence: B)
2011 recommendation remains
current.
receive adequate preparatory hydration 2011 recommendation remains
current.
t the maximum volume of contrast
iated nephropathy (166,167).
2011 recommendation remains
current.
tage 3) CKD (162,163,168,169).
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August 14, 2012:645–81 2012 UA/NSTEMI Focused Updateinical experience, with isotonic or half-normal saline alone
ing the historical gold standards (164,165,182–184). More
cently, sodium bicarbonate has been tested as the hydrating
lution. Some trials have reported superiority of sodium
carbonate over saline in preventing CIN (185–188). Simi-
rly, some have reported a benefit of N-acetylcysteine
ministration as adjunctive therapy to hydration (185,189),
hereas others have not (190,191). Thus, although the
riting group found the evidence compelling for adequate
dration preparatory to angiography with contrast media, it
und the evidence insufficient to recommend a specific
gimen.
With respect to limitation of contrast dose by renal
nction, mounting evidence points to renal-function–specific
mits on maximal contrast volumes that can be given without
gnificantly increasing the baseline risk of provoking CIN. In
contemporary study, Laskey et al studied 3,179 consecutive
tients undergoing PCI and found that a contrast volume to
eatinine clearance ratio 3.7 was a significant and inde-
ndent predictor of an early and abnormal increase in serum
eatinine (166). In an earlier trial, administration of a
ntrast volume of 5 mLbody weight (kg)/serum creati-
ne (mg/dL), applied to 16,592 patients undergoing car-
ac catheterization, was associated with a 6-fold increase
the likelihood of patients developing CIN requiring
alysis (167).
Patients with CKD are consistently underrepresented in
ndomized controlled trials of cardiovascular disease (192).
he impact of an invasive strategy has been uncertain in this
oup. The SWEDEHEART (Swedish Web-System for En-
ncement and Development of Evidence-Based Care in
eart Disease Evaluated According to Recommended Ther-
ies) study included a cohort of 23,262 patients hospitalized
r NSTEMI in Sweden between 2003 and 2006 who were
e 80 years (169). This contemporary nationwide registry
nearly all consecutive patients examined the distribution of
KD and the use of early revascularization after NSTEMI
d evaluated whether early revascularization (by either PCI
CABG) within 14 days of admission for NSTEMI altered
tcomes at all stages of kidney function.
In SWEDEHEART, all-cause mortality was assessed at 1
ar and was available in 99% of patients. Moderate or
ore advanced CKD (estimated glomerular filtration rate
GFR] 60 mL/min per 1.73 m2) was present in 5,689
tients (24.4%). After multivariable adjustment, the 1-year
ortality in the overall cohort was 36% lower with early
vascularization (HR: 0.64; 95% CI: 0.56 to 0.73; p0.001)
69). The magnitude of the difference in 1-year mortality
as similar in patients with normal eGFR (early revascular-
ation versus medically treated: 1.9% versus 10%; HR: 0.58;
ble 9. Recommendation for Quality Care and Outcomes for UA
2012 Focused Update Recommenda
ass IIa
1. It is reasonable for clinicians and hospitals that provide care to patients w
quality-of-care data registry designed to track and measure outcomes, co
processes of care and quality improvement for UA/NSTEMI (194–204). (LeUA/NSTEMI indicates unstable angina/non–ST-elevation myocardial infarction.% CI: 0.42 to 0.80; p0.001), mild CKD [eGFR 60 to 89
L/min per 1.73 m2] (2.4% versus 10%; HR: 0.64; 95% CI:
52 to 0.80; p0.001), and moderate CKD [eGFR 30 to 59
L/min per 1.73 m2] (7% versus 22%; HR: 0.68; 95% CI:
54 to 0.86; p0.001). The benefit of an invasive therapy
as not evident in patients with severe CKD stage 4 [eGFR
to 29 mL/min per 1.73 m2] (22% versus 41%; HR: 0.91;
% CI: 0.51 to 1.61; p0.780) or in those with CKD stage
kidney failure [eGFR15 mL/min per 1.73 m2 or receiving
alysis] (44% versus 53%; HR: 1.61; 95% CI: 0.84 to 3.09;
0.150). Early revascularization was associated with in-
eased 1-year survival in UA/NSTEMI patients with mild to
oderate CKD, but no association was observed in those with
vere or end-stage kidney disease (169).
The findings from SWEDEHEART are limited by their
nrandomized nature and the potential for selection bias
spite the intricate multivariable adjustment (169). On the
her hand, SWEDEHEART captured unselected patients
ith more comorbidities and is therefore more reflective of
al-world patients.
Recently, a collaborative meta-analysis of randomized
ntrolled trials that compared invasive and conservative
eatments in UA/NSTEMI was conducted to estimate the
fectiveness of early angiography in patients with CKD
68). The meta-analysis demonstrated that an invasive strat-
y was associated with a significant reduction in rehospital-
ation (RR: 0.76; 95% CI: 0.66 to 0.87; p0.001) at 1 year
mpared with conservative strategy. The meta-analysis did
t show any significant differences with regard to all-cause
ortality (RR: 0.76; 95% CI: 0.49 to 1.17; p0.21), nonfatal
I (RR: 0.78; 95% CI: 0.52 to 1.16; p0.22), and the
mposite of death/nonfatal MI (RR: 0.79; 95% CI: 0.53 to
18; p0.24) (168).
Our recommendation is that an early invasive strategy (i.e.,
agnostic angiography with intent to perform revasculariza-
on) is a reasonable strategy in patients with mild and
oderate CKD. Clinicians should exercise judgment in all
pulations with impaired kidney function when considering
hether to implement an invasive strategy. Such implemen-
tion should be considered only after careful assessment of
e risks, benefits, and alternatives for each individual patient.
The observational data with regard to patients with mild to
vere CKD also support the recognition that CKD is an
derappreciated high-risk characteristic in the UA/NSTEMI
pulation. The increased risk of mortality associated with
ild, moderate, and severe CKD remains evident across
udies (162,163,168,193). Indeed, the risks of short- and
ng-term mortality are increased as the gradient of renal
sfunction worsens (162,168,193). The optimal role of early
vascularization in this heterogeneous population of patients
I
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scussed earlier in this update (37,156).
. Conclusions and Future Directions
.1. Quality of Care and Outcomes
r UA/NSTEMI: Recommendation
ee Table 9.)
.1.1. Quality Care and Outcomes
he development of regional systems of UA/NSTEMI care is
matter of utmost importance (196,198,199). This includes
couraging the participation of key stakeholders in collab-
ative efforts to evaluate care using standardized perfor-
ance and quality-improvement measures, such as those
dorsed by the ACC and the AHA for UN/NSTEMI (199).
tandardized quality-of-care data registries designed to track
d measure outcomes, complications, and adherence to
idence-based processes of care for UA/NSTEMI are also
itical: programs such as the NCDR (National Cardiovascu-
r Data Registry) ACTION Registry-GWTG, the AHA’s Get
ith The Guidelines (GWTG) quality-improvement pro-
am, and those performance-measurement systems required
The Joint Commission and the Centers for Medicare and
edicaid Services (194,201–203). More recently, the AHA
s promoted its Mission: Lifeline initiative, which was
veloped to encourage closer cooperation and trust among
ehospital emergency services personnel and cardiac care
ofessionals (194). The evaluation of UA/NSTEMI care
livery across traditional care-delivery boundaries with
ese tools and other resources is imperative to identify
stems problems and enable the application of modern
ality-improvement methods, such as Six Sigma, to make
cessary improvements (195,197,200,204). The quality-
provement data coming from registries like the ACTION-
TWG may prove pivotal in addressing opportunities for
ality improvement at the local, regional, and national level,
cluding the elimination of healthcare disparities and con-
ct of comparative effectiveness research.
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Support PCI in UA/NSTEMI
Drug*
During PCI
Comments
– All Patients to Receive ASA
Patient Received Initial
Medical Treatment (With a
P2Y12 Receptor Inhibitor)
Patient Did Not Receive Initial
Medical Treatment (With a P2Y12
Receptor Inhibitor)
ycoprotein IIb/IIIa Receptor Antagonists
Abciximab Of uncertain benefit LD of 0.25 mg/kg IV bolus
MD of 0.125 mcg/kg per min (maximum
10 mcg/min) (Class I, LOE: A)
– Continue for up to 12 h at the discretion of the physician.
Eptifibatide Of uncertain benefit LD of 180 mcg/kg IV bolus followed
10 min later by second IV bolus of 180
mcg/kg
MD of 2.0 mcg/kg per min, started after
first bolus; reduce infusion by 50% in
patients with estimated creatinine
clearance 50 mL/min (Class I, LOE: A)
– Double bolus is recommended to support PCI in STEMI as
the recommended adult dosage of eptifibatide in patients with
normal renal function.
– Infusion should be continued for 12 to 18 h at the
discretion of the physician.
Tirofiban Of uncertain benefit LD of 25 mcg/kg IV bolus
MD of IV infusion of 0.15 mcg/kg per
min; reduce rate of infusion by 50% in
patients with estimated creatinine
clearance 30 mL/min (Class I, LOE: B)
– Increased dosing over previous recommendation.
– Continue for up to 18 h at the discretion of the physician.
– A lower-dose regimen for tirofiban is FDA approved and
has been shown to be effective when used to treat
UA/NSTEMI patients who are started on medical therapy and
when there is a substantial delay to angiography/PCI
(e.g., 48 h):
LD of 50 mcg/mL administered at an initial rate of
0.4 mcg/kg per min for 30 min
MD of a continuous infusion of 0.1 mcg/kg per min.
Continue the infusion through angiography and for 12 to 24 h
after angioplasty or atherectomy.
Y12 Receptor Inhibitors
Clopidogrel† If 600 mg given orally, then
no additional treatment
A second LD of 300 mg
may be given orally to
supplement a prior LD of
300 mg (Class I, LOE: C)
LD of 300–600 mg orally (Class I, LOE: A)
MD of 75 mg orally per d (Class I, LOE: A)
MD of 150 mg orally per d for initial 6 d
may be considered (Class IIb, LOE: B)
– Optimum LD requires clinical consideration.
– Dose for patients 75 y of age has not been established.
– There is a recommended duration of therapy for all post-
PCI patients receiving a BMS or DES.
– Caution should be exercised for use with a PPI.
– Period of withdrawal before surgery should be at least 5 d.
(For full explanations, see footnote.)
Prasugrel‡ No data are available to
guide decision making
LD of 60 mg orally (Class I, LOE: B)
MD of 10 mg orally per d (Class I, LOE: B)
– There are no data for treatment with prasugrel before PCI.
– MD of 5 mg orally per d in special circumstances.
– Special dosing for patients 60 kg or 75 y of age.
– There is a recommended duration of therapy for all post-
PCI patients receiving a DES.
– Contraindicated for use in patients with prior history of TIA
or stroke.
– Period of withdrawal before surgery should be at least 7 d.
(For full explanations, see footnote.)
Ticagrelor Patients who are already
receiving clopidogrel should
receive a loading dose of
ticagrelor
LD of 180 mg orally (Class I, LOE: B)
MD of 90 mg orally twice daily
(Class I, LOE: B)
– The recommended maintenance dose of ASA to be used
with ticagrelor is 81 mg daily.
– Ticagrelor’s benefits were observed irrespective of prior
therapy with clopidogrel (47% of patients in PLATO received
clopidogrel at the time of randomization).
– Period of withdrawal before surgery should be at least 5 d.
– Issues of patient compliance may be especially important
with twice-daily dosing regimen.
– Ticagrelor increases the risk of fatal ICH compared with
clopidogrel and should be avoided in those with a prior
history of ICH. Until further data become available, it seems
prudent to weigh the possible increased risk of intracranial
bleeding when considering the addition of ticagrelor to aspirin
in patients with prior stroke or TIA.(Continued)
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Drug*
During PCI
Comments – All Patients to Receive ASA
Patient Received Initial
Medical Treatment (With a
P2Y12 Receptor Inhibitor)
Patient Did Not Receive Initial
Medical Treatment (With a P2Y12
Receptor Inhibitor)
renteral Anticoagulants
Bivalirudin For patients who have
received UFH, wait 30 min,
then give 0.75 mg/kg
bolus, then 1.75 mg/kg per
h infusion (Class I, LOE: B)
0.75 mg/kg bolus, 1.75 mg/kg per h
infusion
– Bivalirudin may be used to support PCI and UA/NSTEMI
with or without previously administered UFH with the addition
of 600 mg of clopidogrel.
– In UA/NSTEMI patients undergoing PCI who are at high
risk of bleeding, bivalirudin anticoagulation is reasonable.
UFH IV GP IIb/IIIa planned: target
ACT 200–250 s
No IV GP IIb/IIIa planned:
target ACT 250–300 s for
HemoTec, 300–350 s for
Hemochron (Class I, LOE: B)
IV GP IIb/IIIa planned: 50–70 units/kg
bolus to achieve an ACT of 200–250 s
No IV GP IIb/IIIa planned: 70–100 units/kg
bolus to achieve target ACT of 250–300 s
for HemoTec, 300–350 s for Hemochron
(Class I, LOE: B)
*This list is in alphabetical order and is not meant to indicate a particular therapy preference. This drug table does not make recommendations for combinations
listed drugs. It is only meant to indicate an approved or recommended dosage if a drug is chosen for a given situation.
†The optimum LD of clopidogrel has not been established. Randomized trials establishing its efficacy and providing data on bleeding risks used an LD of 300 mg
ally followed by a daily oral dose of 75 mg. Higher oral LDs such as 600 mg or more than 900 mg of clopidogrel more rapidly inhibit platelet aggregation and achieve
higher absolute level of inhibition of platelet aggregation, but the additive clinical efficacy and safety of higher oral LD have not been rigorously established. For
st-PCI patients receiving a DES, a daily MD should be given for at least 12 mo unless the risk of bleeding outweighs the anticipated net benefit afforded by a P2Y12
ceptor inhibitor. For post-PCI patients receiving a BMS, an MD should be given for up to 12 mo (unless the risk of bleeding outweighs the anticipated net benefit
forded by a P2Y12 receptor inhibitor; then it should be given for a minimum of 2 wk). The necessity for giving an LD of clopidogrel before PCI is driven by the
armacokinetics of clopidogrel, for which a period of several hours is required to achieve desired levels of platelet inhibition. Patients who have a reduced-function
P2C19 allele have significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of MACE, including stent
rombosis. In UA/NSTEMI patients taking clopidogrel for whom CABG is planned and can be delayed, it is reasonable to discontinue the clopidogrel to allow for
ssipation of the antiplatelet effect unless the urgency for revascularization and/or the net benefit of clopidogrel outweigh the potential risks of excess bleeding. The
riod of withdrawal should be at least 5 d in patients receiving clopidogrel.
‡Patients weighing60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10-mg once-daily MD. Consider
wering the MD to 5 mg in patients who weigh 60 kg. The effectiveness and safety of the 5-mg dose have not been studied prospectively. For post-PCI patients
ceiving DES, a daily MD should be given for at least 12 mo unless the risk of bleeding outweighs the anticipated net benefit afforded by a P2Y12 receptor inhibitor.
not use prasugrel in patients with active pathological bleeding or a history of TIA or stroke. In patients age75 y, prasugrel is generally not recommended because
the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior myocardial
farction), for which its effect appears to be greater and its use may be considered. Do not start prasugrel in patients likely to undergo urgent CABG. When possible,
scontinue prasugrel at least 7 d before any surgery. Additional risk factors for bleeding include body weight 60 kg, propensity to bleed, and concomitant use of
edications that increase the risk of bleeding (e.g., warfarin, heparin, fibrinolytic therapy, or long-term use of nonsteroidal anti-inflammatory drugs).
ACT indicates activated clotting time; ASA, aspirin; BMS, bare-metal stent; CABG, coronary artery bypass graft; DES, drug-eluting stent; GP, glycoprotein; FDA, Food
d Drug Administration; ICH, intracranial hemorrhage; IV, intravenous; LD, loading dose; LOE, level of evidence; MACE, major adverse cardiac events; MD,
aintenance dose; PCI, percutaneous coronary intervention; PLATO, PLATelet inhibition and patient Outcomes trial; PPI, proton pump inhibitor; STEMI, ST-elevation
yocardial infarction; TIA, transient ischemic attack; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; and UFH, unfractionated heparin.
Modified from Wright et al (6).
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Clopidogrel Prasugrel Ticagrelor
armacology Prodrug—requires conversion to active metabolite
that irreversibly blocks P2Y12 receptor
Prodrug—requires conversion to active metabolite that
irreversibly blocks P2Y12 receptor. Conversion to active
metabolite occurs more rapidly and to a greater
degree than with clopidogrel
Parent compound is active and no biotransformation is
required for reversible inhibition of P2Y12 receptor
ect on platelet
aggregation
There is a delay of several hours before maximal
antiplatelet effect is seen
Onset of antiplatelet effect is faster and extent of
inhibition of aggregation is greater than with
clopidogrel (a significant antiplatelet effect was
observed within 30 min of loading)
Onset of antiplatelet effect is faster and extent of
inhibition of aggregation is greater than with clopidogrel
(a significant antiplatelet effect was observed within
30 min of loading)
nagement
strategy
Conservative Invasive Conservative Invasive Conservative Invasive
Loading dose 300 mg 600 mg Generally not
recommended for
precatheterization
use in UA/NSTEMI
60 mg at time of PCI 180 mg 180 mg
Timing Initiate on presentation Initiate as soon as
possible before or
at the time of PCI
Initiate as soon as
coronary anatomy is
known and decision is
made to proceed with PCI
Initiate on presentation Initiate as soon as
possible before or at
the time of PCI
Maintenance
dose
75 mg
Optimal approach to
dosing in individual
patients based on
genotype and individual
antiplatelet effects not
rigorously established
75 mg
Optimal individual
dose not rigorously
established (see
comment to left).
(150 mg for first 6 d
is an alternative)
10 mg
Consider reduction to
5 mg in patients
weighing 60 kg. The
efficacy (or benefit) of
prasugrel in those age
75 y is uncertain.
Contraindicated in
patients with a history of
stroke or TIA.
90 mg twice daily
(The recommended
maintenance dose of
ASA to be used with
ticagrelor is 81 mg
daily)
90 mg twice daily
(The recommended
maintenance dose of ASA
to be used with ticagrelor
is 81 mg daily)
Duration Ideally up to 12 mo At least 12 mo for
patients receiving DES
Up to 12 mo for
patients receiving
BMS
At least 12 mo for
patients receiving DES
Up to 12 mo for patients
receiving BMS
Ideally up to 12 mo At least 12 mo for
patients receiving DES
Up to 12 mo for patients
receiving BMS
ditional
considerations
Variability of
response
Greater than with prasugrel or ticagrelor. Factors
impacting on response in some patients may include
genetic predisposition to convert parent compound to
active metabolite and drug interactions (e.g., PPIs)
Less than with clopidogrel. Impact of genotype and
concomitant medications appears less than with
clopidogrel.
Less compared with clopidogrel. Impact of genotype and
concomitant medications appears less than with
clopidogrel.
Platelet
function
testing
Clinical utility not rigorously established. May be
useful in selected patients with ischemic/thrombotic
events while compliant with a clopidogrel regimen
Clinical utility not rigorously established but less likely
to be necessary given lesser degree of variation in
response
Clinical utility not rigorously established but less likely to
be necessary given lesser degree of variation in response
Genotyping Identifies patients with a diminished (CYP2C19 2,
3 alleles) or enhanced (CYP2C17 allele) to form
active metabolite. Role of genotyping in clinical
management not rigorously established.
Clinical utility not rigorously established but less likely
to be necessary given lesser degree of variation in
response
Clinical utility not rigorously established but less likely to
be necessary given lesser degree of variation in response
Risk of
bleeding
Standard dosing with clopidogrel is associated with
less bleeding than with prasugrel and ticagrelor.
Higher doses of clopidogrel are associated with
greater risk of bleeding than standard dose
clopidogrel.
Risk of spontaneous, instrumented, and fatal bleeds
higher with prasugrel compared with standard dose
clopidogrel
Risk of non-CABG bleeds higher with ticagrelor compared
with standard dose clopidogrel
Transition to
surgery
Wait 5 d after last dose Wait 7 d after last dose Wait 5 d after last dose
ASA indicates aspirin; BMS, bare-metal stent; DES, drug-eluting stent; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; PPI, proton
mp inhibitor; TIA, transient ischemic attack; and UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction.
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*A loading dose followed by a daily maintenance dose of either clopidogrel (LOE: B), prasugrel (in PCI-treated patients), or ticagrelor (LOE: C) should be administered
UA/NSTEMI patients who are unable to take ASA because of hypersensitivity or major GI intolerance.
†If fondaparinux is used during PCI (Class I, LOE: B), it must be coadministered with another anticoagulant with Factor IIa activity (i.e., UFH).
‡Timing of invasive strategy generally is assumed to be 4 to 48 h. If immediate angiography is selected, see STEMI guidelines.
§Precatheterization triple antiplatelet therapy (ASA, clopidogrel or ticagrelor, GP inhibitors) is a Class IIb, LOE: B recommendation for selected high-risk patients.
so, note that there are no data for therapy with 2 concurrent P2Y12 receptor inhibitors, and this is not recommended in the case of aspirin allergy.
ASA indicates aspirin; CABG, coronary artery bypass graft; D/C, discontinue; GI, gastrointestinal; GP, glycoprotein; IV, intravenous; LOE, level of evidence; PCI,
rcutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; and UFH,
fractionated heparin.
Modified from Wright et al (6).
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rsus Conservative Strategy
Generally
eferred Strategy Patient Characteristics
vasive Recurrent angina or ischemia at rest or with
low-level activities despite intensive medical
therapy
Elevated cardiac biomarkers (TnT or TnI)
New or presumably new ST-segment
depression
Signs or symptoms of HF or new or
worsening mitral regurgitation
High-risk findings from noninvasive testing
Hemodynamic instability
Sustained ventricular tachycardia
PCI within 6 mo
Prior CABG
High-risk score (e.g., TIMI, GRACE)
Mild to moderate renal dysfunction
Diabetes mellitus
Reduced LV function (LVEF 40%)
nservative Low-risk score (e.g., TIMI, GRACE)
Patient or physician preference in the
absence of high-risk features
CABG indicates coronary artery bypass graft; GRACE, Global Registry of
ute Coronary Events; HF, heart failure; LV, left ventricular; LVEF, left
ntricular ejection fraction; PCI, percutaneous coronary intervention; TIMI,
rombolysis In Myocardial Infarction; TnI, troponin I; and TnT, troponin T.
Reprinted from Anderson et al (4).
